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ABSTRACT 
 
Decentralisation of the multidrug resistant tuberculosis (MDR TB) programme to primary 
health care (PHC) facilities in the Nelson Mandela Metropolitan was implemented in 
order to improve the effectiveness of MDR TB services. This study explored the 
knowledge gaps of nurses at PHC facilities as regards MDR TB. A quantitative, cross-
sectional descriptive study was conducted; data was collected using a structured 
questionnaire. Non-probability sampling was applied in this study. A convenient 
sampling technique was used and 25 of the 42 facilities were selected.  Thirty-two 
respondents completed the questionnaire with a response rate of 64%.  Descriptive 
statistics were used to describe the data. Only 38% of the nurses had been trained on 
MDR TB. Overall scores were high with a mean knowledge score of 61%. However 
there were knowledge gaps regarding side effects of MDR TB medication. This study 
revealed gaps in knowledge of certain areas of MDR TB management.  
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CHAPTER 1 
 
ORIENTATION TO THE STUDY 
 
 
1.1 INTRODUCTION  
 
Tuberculosis (TB) remains a major global health problem. An estimated 2 billion people, 
or one-third of the global population, are infected with TB (Olson, Lebovitz & Claiborne 
2011:1). Tuberculosis is an airborne infectious disease resulting in the deaths of 1.8 
million people each year, or 4,500 each day (World Health Organization (WHO) 2009:1) 
despite there being treatment available capable of curing most cases of TB. In addition 
to the harmful effects of TB, there is a growing threat of drug-resistant strains of the 
disease in many parts of the world, threatening the health of the individual as well as the 
community. Based on global drug resistance surveillance data, it was estimated that 3.6 
percent of global TB cases, or a total of 440 000 cases, were multidrug resistant (MDR) 
in 2008 (WHO 2010:18).   
 
South Africa has the third highest TB and the fifth highest MDR TB burden in the world 
(National Department of Health South Africa 2011:v). The number of MDR TB cases 
diagnosed has doubled from 7 386 recorded in 2010 (National Department of Health 
South Africa 2011:4) to 15 400 recorded in 2013 (Gonzalez 2013). Of the nine 
provinces, KwaZulu-Natal and the Eastern Cape shoulder the heaviest burden of MDR 
TB cases in South Africa (National Department of Health South Africa 2011:4).  The 
limited number of bed spaces available at hospitals has resulted in the management of 
MDR TB being decentralised, with nurses at primary health care (PHC) facilities 
consequently having to manage patients diagnosed with MDR TB, a disease that 
formerly was managed in a few of the country’s specialised TB hospitals. There have 
been limited studies documented on the knowledge of nurses in the PHC setting on 
MDR TB. Their knowledge plays an important role in the management of MDR TB, 
especially in areas where a doctor might only be available on certain days. 
 
A study, conducted in Russia, showed that there was a gap in the knowledge observed 
amongst health care workers, including nurses, regarding TB and infection control and 
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that this could increase the risk of acquiring nosocomial infection for TB health care 
workers (Woith, Volchenkov & Larson 2010:1491). 
 
Multidrug resistant TB is an infectious disease, and lack of knowledge creates risk for 
the health care worker as well as influencing the effective management of patients with 
TB and MDR TB in urban and rural areas. The results from this study illustrated the 
knowledge gaps of nurses in an urban PHC setting and provided recommendations to 
address these knowledge gaps. For the purpose of this study, the term ‘nurses’ will refer 
to professional nurses working in PHC facilities, involved in the management of MDR 
TB. 
 
1.2 BACKGROUND TO THE RESEARCH PROBLEM 
 
The background to the research problem is discussed firstly, in terms of decentralised 
management of MDR TB and secondly, in terms of the knowledge of health care 
workers on MDR TB. 
 
• Decentralised management of MDR TB 
 
The South African Department of Health programme dictates that all laboratory 
diagnosed MDR TB patients be hospitalised in a centralised MDR TB hospital until they 
have two consecutive negative TB cultures taken at least 30 days apart (National 
Department of Health South Africa 2011:5). Consequently, patients are hospitalised for 
several months and waiting lists for patients needing admission to these hospitals are 
widespread. In addition, the number of patients diagnosed with MDR TB far exceeds the 
number of beds available per province, with only 2 500 beds available nationally while, 
as mentioned previously, 7 386 patients were diagnosed in 2010 (Ndjeka 2013; National 
Department of Health South Africa 2011:5). For this reason, the National Treatment 
Plan adopted a policy of decentralised management for MDR TB (Padayatchi, Naidoo, 
Dawood, Kharsany & Abdool Karim 2010:95). Decentralised management of MDR TB 
refers to the transfer of responsibility of treating MDR TB patients to lower levels of the 
system such as PHC facilities (National Department of Health South Africa 2011:2). The 
intention of this was to shorten the number of days between diagnosis and treatment 
initiation, increasing treatment coverage, reducing the transmission and making it 
possible for patients to be treated closer to their homes, increasing the acceptability of 
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treatment (National Department of Health South Africa 2011:7). The centralised and 
decentralised MDR TB units would be responsible for initiating and monitoring treatment 
of MDR TB cases, in addition to providing support to PHC facilities. The role of the 
nurse at the PHC facilities would be to identify high risk groups, such as: non-
converters, re-treatment patients and drug resistant contacts; collect sputum for 
microscopy, drug susceptibility testing; contact screening and testing; administering 
injections and medication to all MDR TB patients, monitoring side effects, provide 
ongoing education on adherence, side effects and infection control practices (National 
Department of Health South Africa 2013:18).The process of decentralisation of the 
management of MDR TB thus requires health care workers, and specifically nurses at 
PHC facilities, to have adequate knowledge of MDR TB. 
 
The decentralisation of MDR TB care from hospitals to PHC facilities in the Nelson 
Mandela Metropolitan (NMM) was implemented in October 2011 due to the limited bed 
space and the growing number of patients with MDR TB. By 2014, the TB hospital that 
admits MDR TB patients had the bed capacity to treat 129 MDR TB patients; however, 
there were approximately 500 patients with MDR TB in the NMM district (Jose Pearson 
Hospital: Personal communication 2014). Since the decentralisation of MDR TB, PHC 
facilities play a significant role in the management of MDR TB in the NMM. Patients that 
have MDR TB and who do not require hospitalisation are started on treatment as 
outpatients and then receive care and management by the nurses at the PHC facility. 
The management of the disease entails administering injections and medication to all 
MDR TB patients, monitoring side effects, contact screening, providing ongoing 
education on adherence, side effects, infection control practices as well as managing 
other co-morbidities experienced by the patient (National Department of Health South 
Africa 2011:23). There have, however, been no studies conducted in the Nelson 
Mandela Metropolitan (NMM) to assess the knowledge that nurses possess, on the 
management of MDR TB at PHC facilities. 
 
• Knowledge of health care workers on MDR TB 
 
The researcher conducted a search for studies using the following search engines: 
Ebscohost®, Medline and CINAHL. The keywords used were MDR TB, knowledge and 
nurses. The studies found focused on knowledge of TB. The lack of research, regarding 
nurses’ knowledge of MDR TB, indicated a gap in the literature as well as the fact that 
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the face of managing and treating infectious diseases such as MDR TB is fast changing 
and evolving. 
 
A study in Peru revealed a lack of knowledge amongst doctors and nurses regarding 
assessing treatment outcome of TB (Kiefer, Shao, Carasquillo, Nabeta & Seas 
2009:783; Savicevic 2009:484) while one conducted in Russia indicated that treatment 
and infection control were areas where knowledge was poor (Woith et al 2010:1489). 
Nurses in Turkey lacked knowledge on side effects of TB medication (Yükseltürk & Dinç 
2013:54). In South Africa, a study was conducted in the Western Cape in which the 
experiences of nurses in South Africa with regard to the factors influencing TB infection 
prevention and control were investigated and highlighted, as one of the challenges a 
lack of TB-related training amongst nurses (Sissolak, Marais & Mehtar 2011:6). The 
areas identified by Sissolak et al (2011:6) as requiring training included infectious time 
and infection control. In a study conducted in KwaZulu-Natal amongst doctors and 
nurses, a lack of knowledge of the storage of sputum was highlighted as a challenge 
(Loveday, Thomson, Chopra & Ndlela 2008:1045). 
 
In South Africa, in 2012, the Democratic Nursing Association, launched training on MDR 
TB for nurse educators to include the process and management of MDR TB in the 
nursing curriculum (Denosa 2012:1). The programme encompassed a number of issues 
ranging from diagnosis of Human Immuno-deficiency Virus (HIV) in adults and children, 
the diagnosis of TB and MDR TB in adults and children to infection and control 
prevention as well as community-based care and patient education.  Thus it can be 
seen that training nurses on MDR TB is becoming an important aspect. 
 
The role of the nurse is always evolving and expanding. Faced with the shortage of 
doctors and the burden of HIV/AIDS and TB, South Africa changed policies to allow 
nurses to initiate antiretroviral treatment in 2010 (National Department of Health South 
Africa 2010:7). The chronic shortage of beds at TB hospitals, as well as the increasing 
number of patients, has led to MDR TB management by nurses (National Department of 
Health South Africa 2011:23). Hence the function and responsibility of nurses is 
increasing. 
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1.3 PROBLEM STATEMENT 
 
In 2012, the researcher, as a pharmacist, had received numerous queries from the 
nurses involved with the management of MDR TB patients at the PHC facilities 
regarding the MDR TB medication regimes, management of side effects and 
counselling patients on adherence, as this was previously a hospital managed disease. 
Prior to the decentralisation of MDR TB, nurses only had to identify patients with MDR 
TB and refer them to an MDR TB hospital for care overseen by doctors (National 
Department of Health South Africa 2009). However, due to the growing threat of drug 
resistant TB and the insufficient number of hospitals and doctors to manage MDR TB 
patients, nurses now have to provide care and medication to MDR TB patients at the 
PHC facilities. In addition, most of the PHC facilities in the NMM did not have a full time 
doctor available, resulting in nurses working in the absence of doctor support with 
limited MDR TB training.  
 
As yet, no studies have been conducted in the NMM with regard to the knowledge gaps 
on MDR TB management that nurses at PHC facilities might display. As the South 
African government moves towards nurse-initiated treatment of MDR TB (National 
Department of Health South Africa 2011:2) it is imperative that existing knowledge gaps 
of the nurses on MDR TB be ascertained so that further training can be planned for 
nurses providing care in the PHC setting. Capacitating nurses is essential if global 
initiatives such as the United Nations Millennium Development Goals to halt and 
reverse incidence of TB by 2015 (WHO 2013:1) are to be successful.  
 
1.4 RESEARCH QUESTIONS 
 
The following research question was formulated in the context of the study: 
 
• What knowledge do the nurses working in NMM urban PHC settings have on the 
management of MDR TB? 
 
1.5 PURPOSE OF THE STUDY 
 
The aim of this study was twofold; firstly, to explore the knowledge gaps of nurses 
working at PHC facilities, on the management of MDR TB in the NMM. Secondly, it was 
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to enhance the knowledge of the said nurses working at PHC facilities on the 
management of MDR TB through recommendations based on the study findings. 
 
1.6 OBJECTIVES OF THE STUDY 
 
The objectives of the study were the following: 
 
• Determine the knowledge gaps of nurses working in PHC facilities on the 
management of MDR TB. 
• To improve knowledge gaps of nurses working in PHC facilities on the 
management of MDR TB through recommendations based on the findings of this 
research. 
 
1.7 SIGNIFICANCE OF THE STUDY 
 
There are not enough beds at TB hospitals to accommodate all the cases of MDR TB 
as indicated in the background of this study. Primary health care facilities treatment for 
MDR TB has gained increased recognition as the most effective, efficient and ethical 
means of delivering care to patients with MDR TB (TBCare 2012). The PHC MDR TB 
programme was implemented in the NMM district in 2011. It is essential to identify 
knowledge gaps of these nurses in order to make recommendations for addressing 
these. This study will contribute towards providing a baseline analysis of the said gaps 
to enhance nurses’ training. This in turn will capacitate nurses and improve the effective 
management of patients diagnosed with MDR TB.  
 
1.8 DEFINITION OF KEY TERMS 
 
• Knowledge − Oxford Online Dictionary (2013) defines knowledge as facts, 
information, and skills acquired through experience or education. 
• Management − Oxford Online Dictionary (2013) defines management as the 
treatment or control of diseases or disorders, or the care of patients who suffer 
from them. 
• Multidrug resistance tuberculosis (MDR TB) − The National Department of Health 
South Africa (2013:1) defines MDR TB as a TB disease where there is in vitro 
resistance to both Isoniazid and Rifampicin, with or without resistance to other 
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anti-TB drugs. As Isoniazid and Rifampicin are the two most important first-line 
TB drugs, their exclusion through resistance from the anti-TB drug list has 
serious implications. In this study MDR TB management will refer to the 
management that nurses in PHC facilities have to provide: collecting sputum for 
microscopy, drug susceptibility testing or line probe assay; contact screening and 
testing; administering injections and medication to all MDR TB patients, 
monitoring side effects, providing ongoing education on adherence, side effects 
and infection control. 
• Nurse − Is a person registered as a nurse under section 16 of the Nursing Act no 
50 of 1978, as amended (South Africa 1997b, section 16). (South African Nursing 
Council 2012:1). In this study, a nurse will refer to the professional nurses 
working in PHC facilities, involved in the management of MDR TB patients.  
• Nurse’s knowledge − In this study knowledge will refer to the knowledge that 
nurses working in PHC facilities have on the management of MDR TB. 
• Primary health care facilities −  The National Department of Health South Africa 
(1997:22) defines primary health care facilities as a health care centre, which 
offers comprehensive primary health care to patients including a TB care and 
treatment service. In this study, the PHC facilities were part of the urban areas of 
the Nelson Mandela Metropolitan.  
 
1.9 RESEARCH DESIGN AND METHODOLOGY 
 
According to Polit and Beck (2012a:741), a research design is described as the overall 
plan for addressing a research question, including strategies for enhancing the study’s 
integrity. Chapter 3 includes a more detailed review of this section and the under 
mentioned discussion is merely a brief overview of the research methods. 
 
The researcher adopted a quantitative, cross-sectional, descriptive design in order to 
give a description of the respondents’ knowledge gaps. 
 
1.9.1 Quantitative research 
 
Polit and Beck (2012a:739) describe quantitative research as the ‘investigation of 
phenomena that lend themselves to precise measurement and quantification, often 
involving a rigorous and controlled design’. Quantitative research allows for generation 
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of numerical data that can be interpreted, organised and presented. In this study, the 
research design was quantitative as the researcher used a structured questionnaire to 
collect data from the respondents in order to measure their knowledge gaps. 
 
1.9.2 Descriptive research 
 
Descriptive studies involve observing, describing and documenting aspects of a 
situation as it naturally occurs (Polit & Beck 2012a:226). In this study, the researcher 
aimed to describe the knowledge gaps, on the management of MDR TB, of nurses 
working in PHC facilities. 
 
1.9.3 Cross-sectional research 
 
Cross-sectional studies entail the collection of data at one point in time and are 
appropriate for discussing a phenomenon at a fixed point (Polit & Beck 2013:162). In 
this study a sample of nurses from the PHC facilities were included and the 
questionnaire was administered at one point in time. The data obtained were 
representative of that point in time only.  
 
1.9.4 Study setting 
 
The research setting is the environment in which the research study takes place and 
may be a natural or controlled environment. Natural settings are real-life study 
environments without any changes made for the purpose of the study. (Burns, Grove & 
Gray 2012:373) This research was conducted in urban PHC facilities in the NMM, 
Eastern Cape Province of South Africa. More detail is provided in Chapter 3.  
 
1.9.5 Study population 
 
According to Polit and Beck (2012a:59) a population is defined as all the individuals or 
objects with common, defining characteristics. In this study, the target population is 
those nurses working in PHC facilities with MDR TB patients, in the NMM district of the 
Eastern Cape Province of South Africa.  
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1.9.6 Sample and sampling 
 
Polit and Beck (2012a:290) describe sampling as ‘the process of selecting a portion of 
the population to represent the entire population’. The advantage of selecting a sample 
is that it is less costly and time consuming than collecting information from a large group 
of respondents. Before sampling, the researcher obtained a list of all the PHC facilities 
in the NMM district. There are 42 facilities in the NMM district. As the distances between 
these facilities are considerable, the researcher selected 25 facilities to be included in 
the study. The sites were chosen using the convenience technique. Convenience 
sampling is also known as ‘accidental sampling’ and respondents are usually those that 
are nearest and most easily available (Strydom 2011:232). Convenience sampling is 
also used because of money savings (Cottrell & McKenzie 2011:132). In this study 
convenience sampling was used due to the researcher’s lack of resources and budget 
constraints. The researcher chose facilities that were easy to access and focused on 
those facilities which were nearest, most available and approachable for the researcher.  
 
1.9.7 Sample size 
 
Burns et al (2012:367) state that there are no hard and fast rules about a sample size 
but that a sample should contain at least thirty respondents. Grinnel and Williams 
(1990:127) as cited in De Vos, Strydom, Fouche and Delport (2011:225) contend that 
thirty is sufficient to perform basic statistical actions.  According to Polit and Beck 
(2012a:285), most nursing studies use samples of convenience. In this study the total 
population was small. As there are usually two nurses in the TB unit at a PHC facility, 
the sample size for this study was 50 respondents, of which 32 participated. All the 
available nurses who were willing to participate were invited to take part in this study. 
The shortage of nurses at the facilities due to absenteeism and redistribution of nurses 
to other clinical areas also contributed to the small sample size.  Chapter 3 provides 
more detail in this regard. 
 
1.9.8  Data collection  
 
Data collection is an organised process in which the researcher collects information 
relevant to attain the research purpose and objectives. In quantitative studies the data 
collected is usually numerical (Burns et al 2012:45). In this study, the measuring 
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instrument was in the form of a questionnaire developed by the researcher (Annexure 
B). The main sections of the questionnaire included Section 1, which included 
biographical information of the respondents, Section 2, which asked general questions 
regarding the training received by respondents and Section 3, which contained Likert 
scale type questions on the management of MDR TB. The questionnaire is discussed in 
more detail in Chapter 3 under the section titled Data Collection Instrument. 
 
1.10 VALIDITY AND RELIABILITY 
 
Validity is a quality criterion referring to the degree to which inferences made in a study 
are accurate and well founded (Polit & Beck 2012a:244). Reliability is defined as the 
degree of consistency or dependability with which an instrument measures an attribute 
(Polit & Beck 2012a: 331). The concepts of validity and reliability are discussed in detail 
in Chapter 3. Validity was ensured by performing a literature review, involving experts in 
the construct of the questionnaire and doing a pre-test. Reliability was measured using 
the Cronbach’s Alpha co-efficient.  
 
1.11 DATA ANALYSIS 
 
The responses to the questionnaires were edited and then captured by the researcher 
to form a data set for analysis. This process involved converting the collected data into 
an organised visual representation so that it facilitated data analysis. The data were 
then captured and analysed using the SPSS version 20.0 computer software 
programme by a statistician. Descriptive statistics were used to synthesise and describe 
the data as defined by Polit and Beck (2012a:379) and in this study, also used to 
analyse the data in relation to each question. A pre-test was done to ensure the content 
validity and reliability of the questionnaire and to identify flaws, prior to the 
administration of the questionnaires to the respondents (Polit & Beck 2012a:247). The 
results from the pre-test were not included in the final study, but were used by the 
researcher to refine the questions in the questionnaire. 
 
The data were then presented in frequency tables, pie and bar graphs and discussed in 
detail in Chapter 4. 
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1.12 LIMITATION OF THE STUDY 
 
The limitation of this study included the small sample size, while the facilities were 
limited to one district in the Eastern Cape Province only. The small sample size was 
justified by the shortage of nurses in the PHC setting (refer to the research setting in 
Chapter 3 for more detail and literature to support this). This means that the results and 
conclusions cannot be generalised to other areas. More details are provided in Chapter 
5. 
 
1.13 ETHICAL CONSIDERATIONS 
 
Ethical clearance to conduct the study was obtained from the Higher Degrees 
Committee of the Department of Health Studies, University of South Africa Research 
and Ethics (Annexure A). Permission was sought from the Eastern Cape Department of 
Health (Annexure C) as well as the District Manager of Nelson Mandela Metropolitan 
(Annexure D). In addition, the nurse in charge of the facility was informed prior to the 
administration of the questionnaires.  During the current research, the ethical principles 
of the Declaration of Helsinki were considered and followed. These were beneficence, 
respect for human dignity and justice (Declaration of Helsinki 2013). These are 
discussed in detail in Chapter 3. 
 
1.14 OUTLINE OF THE STUDY 
 
This study contains five chapters as outlined below. 
 
Chapter 1  Orientation to the study 
Chapter 2  Literature review 
Chapter 3  Research design and methodology 
Chapter 4  Analysis, presentation and description of the research findings 
Chapter 5 Findings, conclusion, limitations and recommendations 
 
1.15 CONCLUSION 
 
A literature review is an important component of the research process and in this study 
allowed the researcher to understand the topic, refine the research question and 
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provided information on research methodology. In addition the information gained from 
the literature review assisted the researcher in the development of the questionnaire. 
 
This chapter provided an overview of the problem statement, objectives, research 
questions, significance of the study, the research design and methodology. A 
quantitative, descriptive and cross sectional research design was chosen, using 
structured questionnaires to collect data on the knowledge of nurses about MDR TB.  
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CHAPTER 2 
 
LITERATURE REVIEW 
 
 
2.1 INTRODUCTION 
 
According to De Vos, Fouche and Delport (2011:134), a literature review ‘serves to put 
the researcher’s efforts into perspective’ and should be commenced early on in the 
research process. The literature review provides readers with the necessary knowledge 
and information that allow for a good understanding of the topic under investigation, and 
provides the foundation on which the questionnaire was developed and the new 
knowledge generated by the study will be based. Journal articles, books, policy 
documents and electronic sources such as Ebscohost® (2013), CINAHL and Medline 
(2013) were used in the review of the literature.  The researcher used the keywords: 
MDR TB, knowledge and nurses. There were 141 hits in Ebscohost®, of which 14 were 
related to care and treatment and therefore applicable to this study. The reference lists 
of relevant research articles were also reviewed. During the literature review process, 
the researcher focused on both the global and South African contexts of MDR TB. 
Literature on the decentralisation programme for MDR TB in South Africa was also 
examined (National Department of Health South Africa 2011). 
 
Discussion arising from the literature review assisted in the development of the 
questionnaire and takes place under the following headings: Epidemiology of 
tuberculosis; Global and national phenomenon of MDR TB; HIV and MDR TB, 
Development of MDR TB; Signs and symptoms of MDR TB; Diagnosis and treatment of 
MDR TB; Management of contacts; Patient counselling; Infection control plan and 
Decentralisation of MDR TB management and care.  
 
2.2 EPIDEMIOLOGY OF TUBERCULOSIS 
 
Tuberculosis continues to be a major global health problem and is one of the world’s 
most infectious diseases. Although the causative organism, Mycobacterium (M) 
tuberculosis, was documented over 100 years ago, TB programmes still have difficulty 
in controlling the disease (Jain, Gyanu, Nimmagadda, Pomper & Bishai 2008:285), 
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which causes ill health among millions of people each year: according to the WHO 
(2013), TB ranks as the second leading cause of death from an infectious disease 
worldwide, after HIV. Despite there being treatment available to treat TB, the disease 
continues to be a global health concern (WHO 2011:3). In 1993, the WHO declared TB 
a global public health emergency.  By 2011, there were an estimated 8.7 million new 
cases of TB (13% co-infected with HIV) and 1.4 million people died from TB, including 
almost one million deaths among HIV-negative individuals and 430 000 among people 
who were HIV-positive (WHO 2012:3). 
 
According to the Merck Manual (2011), TB is a chronic infectious disease characterised 
by a long and variable incubation period. The interval between infection, with the 
bacterium M. Tuberculosis, and either a demonstrable primary lesion or significant 
tuberculin reaction is about 4-12 weeks (Sharma 2013:246). The transmission of TB is 
almost entirely by droplet infection from a source case who is coughing and producing 
sputum contaminated with M. tuberculosis (Knechel 2009:35). 
 
Effective treatment of tuberculosis is possible using the first line drugs Isoniazid, 
Rifampicin, Pyrazinamide and Ethambutol (National Department of Health South Africa 
2011:31). According to Sarkar and Suresh (2011:148), this first line therapy often fails to 
cure TB for several reasons. Firstly, the treatment regimen is long, consisting of an 
initial 2 months of intensive phase treatment with all four drugs, followed by the 
continuation phase for 4 months with Isoniazid and Rifampicin. Secondly, the long 
treatment period often results in a lack of compliance, causing treatment failure and 
contributing to the emergence of drug resistant bacteria.  
 
2.3 MULTIDRUG RESISTANT TUBERCULOSIS – A GLOBAL AND NATIONAL 
PHENONOMEN 
 
A large percentage of TB cases are able to be treated effectively with available 
antibiotics (Jain et al 2008:285). However, MDR TB strains are emerging. These strains 
are resistant to the two principal, first line, TB drugs (Rifampicin and Isoniazid) and are 
a major and growing global concern (Institute of Medicine National Academies 2009).  
 
The increase in the number of reports of MDR TB from around the world prompted the 
start of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance by WHO 
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in 1994 (WHO 2009). Since then, drug resistance data has been collected and analysed 
from 135 countries, accounting for 70% of WHO’s 194 Member States. The data in 
these reports indicate that MDR TB is increasing and ubiquitous (Weyer 2005:75; WHO 
2012:41).  
 
The median values for the estimated proportion of TB cases that have MDR TB is 4.3% 
in new patients and 21% in retreatment patients amongst the 27 high MDR TB burden 
countries in the WHO region (WHO 2012:23), while the overall burden is considerable 
at an estimated 630 000 (United Nations 2013). 
 
The spread of MDR TB continues. The WHO (2012:42-43) Global Report on 
Tuberculosis outlines the data on the extent of drug resistant TB. Figure 2.1 reveals the 
percentage of MDR TB amongst all new cases of TB while Figure 2.2 indicates the 
percentage of previously treated TB cases with MDR TB. From these figures it may be 
observed that the darker the intensity of the colour the higher the percentage of MDR 
TB. Globally, 3.7% of new cases and 20% of previously treated cases are estimated to 
have MDR TB. Both figures provide evidence that Eastern Europe and central Asian 
countries represent the areas most affected with MDR TB, with proportions of new TB 
cases with MDRTB ranging from 0% to 32.3% (WHO 2012:42).  
 
 
Figure 2.1 The percentage of new cases with multidrug resistant tuberculosis 
Source: (WHO 2012:43) 
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China also faces a serious MDR TB burden and in 2007, a third of new patients and 
one-half of previously treated TB patients had drug resistant TB (Zhao, Xu, Wang, Chin, 
Wang, Jiang, Xia, Zhou, Li, Ou, Pang, Song, Zhao, Zhang, He, Guo & Wang 2012). The 
prevalence of MDR TB among new patients was 3.5 times the global median and 
double the global average (WHO 2010). 
 
There has been an increase in the number of MDR TB cases notified in the high MDR 
TB countries with some countries, including India, the Philippines, The Russian 
Federation, South Africa and Ukraine each enrolling more than 2000 patients in 2011 
(WHO 2012:47).  
 
 
 
Figure 2.2 Percentage of previously treated cases with multidrug  
resistant tuberculosis 
Source: (WHO 2012:43) 
 
Data from African countries on MDR TB is very scarce despite the high prevalence of 
TB, with the African region accounting for 24% of the world’s TB cases (in WHO 
2012:2). In a 2008 study that gathered estimates of MDR TB rates in African countries, 
the proportion of MDR TB among all TB cases varied from 5.8% in the Democratic 
Republic of Congo to virtually 0% in Kenya. The median MDR TB rate was 1.9% (Amor, 
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Nemser, Singh, Sankin & Schluger 2008:1347). Ethiopia and Nigeria are among the 27 
high MDR TB burden countries in the WHO region, together with South Africa (Wells, 
Cegielski, Nelson, Laserson, Holtz, Finlay, Castro & Weyer 2007:96). 
 
Together with the Russian Federation, China and India, South Africa accounted for 60% 
of all reported MDR TB cases among notified TB patients in 2011 (WHO 2012:41). 
Patients with MDR TB have been diagnosed in all provinces of South Africa since the 
mid-eighties (Weyer 2005:75). A recent national survey by the Medical Research 
Council indicated an overall MDR TB prevalence of 2.9%, arising from 1.8% of new TB 
cases and 6.7% of previously treated cases (WHO 2012:23). Given the high TB burden, 
these relatively low prevalence levels translate into a high burden of at least 8000 MDR 
TB cases estimated per year. The financial burden of the MDR TB epidemic is already 
severe, given that a case of MDR TB costs up to 100 times more to treat than an 
uncomplicated drug-susceptible case (Weyer 2005:75). Furthermore, suboptimal TB 
control, together with the rapidly progressing HIV epidemic, creates a fertile 
environment for transmission of MDR TB. Epidemiological and genetic studies have 
confirmed on-going transmission of drug-resistant TB (Calver, Falmer, Murray, Strauss, 
Streicher, Hanekom, Liversage, Masibi, van Helden, Warren and Victor 2010:264). In 
2010 the National Health Laboratory Services (NHLS) diagnosed 7386 MDR TB cases 
(National Department of Health South Africa 2011:4), with KwaZulu-Natal and the 
Eastern Cape having the highest burden of MDR TB cases in South Africa. 
 
2.4 HIV AND MDR TB 
 
One of main reasons why controlling tuberculosis is failing is the presence of HIV, 
particularly in settings with a high HIV prevalence. Sub-Saharan Africa shoulders the 
highest burden of HIV infections in the world and accounts for 75% of the global AIDS 
deaths (WHO 2013). One of the earliest opportunistic diseases to develop amongst 
patients infected with HIV is tuberculosis (Sethi, Mewara & Dhatwalia, Singh, Yadav, 
Singh, Gupta, Wanchu & Sharma 2013:1) making TB the major cause of death among 
people living with HIV (WHO 2011). 
 
HIV co-infection complicates TB therapy and is associated with delays in diagnosis and 
poorer treatment outcomes. In addition, both TB and HIV are responsible for disarming 
the immune response in a host through mechanisms that are not fully understood while 
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HIV co-infection increases the risk of latent TB reactivation 20-fold (Getahun, 
Gunneberg, Granich & Nunn 2010:3). Whether HIV is a risk factor for the development 
of MDR TB is still a subject under debate. Some studies show no overall association 
between MDR TB and HIV (Suchindron, Brouwer & Van Rie 2009:6) but these studies 
were undertaken prior to the HIV and TB co-epidemic (Getahun et al 2010:3). 
Nonetheless, several studies have established an increased risk of MDR TB in patients 
infected with HIV (Wells et al 2007:86; Gandhi, Moll, Sturm, Pawinski, Govender, Lalloo, 
Zeller, Andrews & Friedland 2006:1575). 
 
Regardless of whether HIV is an independent risk factor for the development of MDR 
TB or not, the large numbers of HIV infected people who have and who transmit both 
TB and MDR TB, are bound to increase the overall burden of drug resistant TB 
(Andrews, Shah, Ghandi, Moll & Friedland 2007:482). Moreover, the risk of patients with 
HIV developing active TB increases to 5-10% annually (Centre for Disease Control 
2013:12). 
 
The development of MDR TB, signs and symptoms, diagnosis and treatment are 
discussed next.  
 
2.5 DEVELOPMENT OF MDR TB 
 
The ability of the TB bacterium to undergo a slow and constant mutation is a natural 
phenomenon that results in resistant organisms developing.  In order for MDR TB 
organisms to develop, a high bacterial load is required. (Weyer 2005:75) 
 
These mutations are spontaneous and occur in the chromosome of the TB bacterium. 
When resistant organisms develop, they result in a decrease in the organism’s 
susceptibility to specific drugs (Colijn, Cohen, Ganesh & Murray 2011:1). This 
development of MDR TB is not a recent occurrence but has evolved over a 
considerable period and is an expected result due to the use of antibacterial agents 
(Fauci 2008:1494).  To an extent, the problem is due to sub optimal drug levels, 
enabling the development of resistant bacteria, or to infection with a drug resistant strain 
(Andrews et al 2007:482). Inadequate treatment, such as direct or indirect 
monotherapy, or non-adherence to the medication, exacerbates the problem, making 
MDR TB a potentially fatal disease (Weyer 2005:76). 
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2.6 SIGNS AND SYMPTOMS OF MDR TB 
 
The symptoms of MDR TB are the same as for drug susceptible TB:  cough, chest pain, 
dyspnoea, haemoptysis and systemic symptoms such as fever, chills, night sweats, 
tiredness, anorexia, and weight loss (Paauw 2013:553). The South African Policy 
Guideline for the Management of MDR TB indicates that in addition to the systemic 
effects of MDR TB, there may be isolated signs unrelated to the site of involvement. 
These include haematologic abnormalities, hyponatraemia and psychological disorders. 
The most common haematological manifestations include increases in the peripheral 
blood leukocyte count and anaemia. (National Department of Health South Africa 
2013:34). 
 
In order to identify patients with MDR TB, nurses at the PHC facilities need to recognise 
the signs and symptoms of MDR TB. In this way, delays in diagnosis and treatment of 
patients with MDR TB are prevented.  
 
2.7 DIAGNOSIS OF MDR TB 
 
The identification and treatment of infected patients is the primary strategy for the 
control of TB (Yagul, Perales, Asencios, Vergara, Suarez, Yale, Salazar, Saavedra, 
Shin, Ferrousier & Cegielski 2006:838). The non-specificity of clinical features of TB and 
the technical demands in identifying and determining drug susceptibility of TB in clinical 
specimens make the diagnosis of MDR TB difficult and extremely challenging (Nachega 
& Chaisson 2003:24). 
 
Multidrug resistant TB should be suspected in patients who continue to have  positive 
acid fast bacilli smears or cultures despite being on adequate treatment  (Weyer 
2005:75). In addition, MDR TB should also be suspected in the close contacts of MDR 
TB patients, particularly those who are immune-compromised (Seung, Omatayo, 
Keshavjee, Furin, Paul, Farmer & Satti 2009:2). According to Weyer (2005:75) MDR TB 
can, however, only be diagnosed by in vitro confirmation of resistance, that is by 
detecting resistance to antimicrobial agents by a clinical microbiology laboratory 
(Jorgensen & Ferraro 2009:1749).  An inadequate clinical response in an adherent 
patient is often supported by a positive smear at 2/3 months, which should prompt a 
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request for culture and Drug Susceptibility Testing (DST) against Isoniazid, Rifampicin 
and Ethambutol. The culture and DST should be carried out if by the end of the 
treatment the sputum remains positive or the patient has not shown an adequate clinical 
response. (Weyer 2005:75) In addition, the close contacts of an MDR TB patient should 
also be investigated for MDR TB, especially if signs and symptoms exist (National 
Department of Health South Africa 2011:23). 
 
The clinical appearance of MDR TB patients is the same as that of patients diagnosed 
with drug susceptible TB disease and the radiological features are undifferentiated. 
However, the diagnosis of MDR TB is dependent on the quality of laboratory 
techniques. A single laboratory report of MDR TB without supporting clinical evidence 
should therefore be treated with caution, and follow-up investigations should be 
requested (Weyer 2005:75). 
 
It is important for nurses to acquire knowledge about the diagnosis of MDR TB as 
nurses usually collect the sputum for culture as well as DST and submit it to the NHLS. 
However, there are different diagnostic tools available, one of them being the 
‘GeneXpert’.  When the results are received, those patients with suspected MDR TB are 
referred to the TB hospital.  
 
2.7.1 The use of ‘GeneXpert’ in the diagnosis of MDR TB 
 
‘GeneXpert’ is a relatively new diagnostic tool for TB diagnosis in South Africa. The 
‘GeneXpert’ assay is a fully automated molecular diagnostic test for TB disease that can 
detect MDR TB directly from sputum specimens in less than 2 hours (Helb, Jones, 
Story, Boehme, Wallace & Ho 2010:18). The advantage of this test over the existing TB 
smear microscopy is its higher sensitivity and specificity so that it identifies many 
patients that would not have been diagnosed using TB microscopy. The ‘GeneXpert’ 
test reports TB as detected or not detected and also provides data on the state of 
susceptibility or resistance to Rifampicin (National Department of Health South Africa 
2013:37).  
 
At PHC facilities, nurses collect sputum from patients and either send it to a laboratory 
for diagnosis or insert the sputum into the ‘GeneXpert’ machine. Nurses in this setting 
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should have knowledge of the ‘GeneXpert’ as a diagnostic tool. Those patients who are 
reported as having resistance are referred to the TB hospital for treatment.  
 
2.8 TREATMENT OF MDR TB 
 
In contrast to those drugs used to treat TB, the treatment of MDR TB requires reserve 
drugs that are much more expensive and more toxic (Ormerod 2005:17) than TB drugs. 
The treatment of MDR TB is long and patients face the real possibility of not surviving. 
As a result, in addition to the medication, they need intensive counselling and support 
(Weyer 2005:75; National Department of Health South Africa 2011:23). At PHC facilities 
where MDR TB patients are treated, the nurses provide their medication, the treatment, 
counselling and support (National Department of Health South Africa 2013:18). 
 
Since 2000, all MDR TB centres in South Africa have used a standardised 
programmatic management of MDR TB called the DOTS-Plus programme, allowing 
clinicians to follow a standard method of patient management and treatment (Farley, 
Ram, Pan, Waldman, Cassell, Chaisson, Weyer, Lancaster & Van der Walt 2011:2). 
 
The standardised approach to DOTS-Plus in South Africa comprises the following: 
 
• Treatment at a dedicated MDR TB hospital where patients are admitted for at 
least the first four months of MDR TB treatment or preferably until the sputum 
has converted. This is defined as two consecutive negative cultures taken at 
least 30 days apart. Patients are then discharged to designated PHC facilities 
with the supply of the required medication. 
• There are specialised teams overseeing all aspects of MDR TB management at 
the referral centres. 
• The MDR TB regimen is a standardised treatment regimen, based on the 
Ethambutol resistance profile of the diagnostic strain and with drug administration 
standardised across three patient weight bands. 
• Regular monitoring of patients during treatment, involves extensive 
documentation. All MDR TB patients must be registered in the DOTS-Plus 
Electronic Register at the MDR TB hospitals. This database contains all 
information necessary for patient management and follow-up, drug adverse effect 
monitoring and final treatment outcomes. 
• Ambulatory treatment after discharge, provided that directly observed treatment 
is ensured. 
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• Patient follow-up for 5 years after treatment completion. Six-monthly visits are 
required to assess symptoms and signs of recurrence (National Department of 
Health South Africa 2004). 
 
The policy guideline for the DOTS-Plus programme was written in 2004; however, it was 
intended for use by health professionals caring for patients with MDR TB. Since the 
decentralisation of MDR TB, it is another programme area with which nurses at PHC 
facilities need to be familiarised, to enhance the management of MDR TB treatment.  
 
2.8.1 Standardised MDR TB Regimen 
 
A standardised regimen for the treatment of MDR TB includes multiple second line 
drugs, not previously used by the patient. The duration of treatment is usually a 
minimum of 18-24 months. In South Africa, the standardised regimen consists of at 
least six months’ intensive phase of daily treatment with five drugs: 
Kanamycin/Amikacin, Moxifloxacin/Levofloxacin, Ethionamide, Terizidone and 
Pyrazinamide. This phase is followed by a continuation phase, utilising four drugs: 
Moxifloxacin, Ethionamide, Terizidone and Pyrazinamide (National Department of 
Health South Africa 2013:42-46). Table 2.1 lists the drugs used to treat MDR TB as well 
as the customary dosages.  
 
TABLE 2.1 SECOND LINE DRUGS USED TO TREAT MDR TB 
 
DRUG DOSAGE 
Injectables  
Kanamycin (KM) 15 mg/kg intramuscularly once daily 
Amikacin (AMK) 15 mg/kg intramuscularly once daily 
Capreomycin (CM) 1 5mg/kg intramuscularly once daily 
Fluroquinolones  
Ciprofloxacin 750 mg orally twice a day 
Levofloxacin 500 mg orally once daily 
Moxifloxacin 400 mg orally once daily 
Gatifloxacin 400 mg orally once daily 
Other second line drugs  
Ethionamide 500-1000 mg orally once daily 
Prothionamide 500-1000 mg orally once daily 
Cycloserine (CS) 500-1000 mg orally once daily 
Clofazimime (CFZ) 200-300 mg orally once daily 
 
(Source: Furin 2007:21) 
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Many of the drugs used in the second line treatment are highly toxic and adverse drug 
reactions (ADRs) are described in a few MDR TB cohort studies (Nathanson,  
Lambregts-van Weezenbeek, Rich, Gupta, Bayona, Blöndal, Caminero, Cegielski, 
Danilovits, Espinal, Hollo, Jaramillo, Leimane, Mitnick, Mukherjee, Nunn, Pasechnikov, 
Tupasi, Wells, Raviglione, & Rich 2006:1393; Shin, Furin, Bayona, Mate, Kim & Farmer  
2004:1529; Shean, Wilcox, Siwendu, Laserson, Gross, Kammerer, Wells & Holtz 
2008:1182). Table 2.2 shows the common adverse effects of the drugs used for the 
treatment of MDR TB. Primary health care nurses are able to monitor ADRs each time a 
patient receives treatment and refer the patient to the TB hospital if required. It is 
therefore important for the nurses to gain an understanding of the MDR TB medication 
and the ADRs associated with the treatment. 
 
TABLE 2.2 ADVERSE EFFECTS OF SECOND LINE DRUGS  
 
SYSTEM 
MILD ADVERSE 
REACTION 
MODERATE TO 
SEVERE ADVERSE 
REACTION 
LIKELY AGENT 
Neurologic Dizziness 
Headache 
Fatigue 
Insomnia 
Seizures 
Peripheral 
neuropathy 
Ototoxicity 
Optic neuritis 
Cycloserine, 
Kanamycin, Amikacin, 
Capreomycin, 
Fluroquinolones 
Psychiatric Depression 
Irritability 
Anxiety 
Mood/behaviour 
changes 
Psychosis 
Suicidal ideation 
Cycloserine 
Renal and Electrolyte  Renal failure 
Hypokalemia 
hypomagnesemia 
Cycloserine, 
Kanamycin, Amikacin, 
Capreomycin 
Dermatological Change in skin 
colour 
Photosensitivty 
Anaphylaxis 
Stevens-Johnson 
syndrome 
Clofazimine, plus all 
drugs can cause rare 
dermatological adverse 
reactions 
 
(Source: Furin 2007:212) 
 
In addition to treating the MDR TB patient, PHC nurses need to manage the contacts of 
MDR TB patients, discussed in the next section. 
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2.9 MANAGEMENT OF MDR TB CONTACTS 
 
‘Close contacts’ of MDR TB patients refers to those persons living in the same 
household as the MDR TB patient, or who spend many hours a day together with the 
patient in the same indoor space (National Department of Health South Africa 
2013:103). In order to decrease the risk of transmission of MDR TB, household infection 
control measures should be applied by the patient and the family (Cobelens, Heldal, 
Kimerling, Mitnick & Podewils 2008:1040). 
 
Two of the categories of close contacts that are at high risk of contracting MDR TB are 
those patients who are immunocompromised with HIV, and children. In patients who 
have a compromised immune system, the risk of developing active MDR TB is highest 
within the first 2 years following infection (National Department of Health South Africa 
2013:102). Children who are contacts of MDR TB patients are at a higher risk of 
developing active MDR TB soon after infection, especially children under 2 years of age 
(Marais, Gie, Schaaf, Hesseling, Obihara, Starke, Enarson, Donald & Beyers 2004).  
Although HIV is the most common reason for immune deficiency in South Africa, it 
should be kept in mind that impaired immunity can also result from malnutrition, 
congenital syndromes, haematological diseases, endocrine or renal disease and 
diabetes mellitus. Patients who are receiving immunosuppressive drugs or radiation 
therapy may also be at increased risk of active MDR TB after exposure. (Onyango 
2011:3). 
 
The management of asymptomatic contacts of MDR TB is carried out in the same 
manner as contacts of drug susceptible TB as there is a possibility that they could have 
been infected with a drug susceptible strain (National Department of Health South Africa 
2013:103). Isoniazid Preventative Therapy is therefore prescribed to prevent drug 
susceptible TB, not MDR TB. All child contacts aged 5 years and younger should 
receive preventive therapy with Isoniazid once active TB has been excluded (Newton, 
Brent, Anderson, Whitaker & Kampmann 2008:10). In children older than five years, as 
well as in adult contacts, a careful risk assessment is required and MDR TB must be 
confirmed before treatment with Isoniazid is started (University Research Company 
2013). The South African guideline for the management of MDR TB includes a complete 
medical history (for example, assessing cough, sputum production, fever and weight 
loss), physical examination and bacteriological investigations as part of the risk 
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assessment (National Department of Health South Africa 2013:34). This assessment 
should be performed by the PHC nurses for every contact when they visit the PHC 
facility. Capacitating the PHC nurse on the management of contacts of MDR TB 
patients will assist in identifying those patients who develop symptoms of TB and MDR 
TB earlier.  
 
The management of symptomatic contacts of MDR TB who do not have TB includes 
treatment with a broad spectrum antibiotic that is not active against tuberculosis such as 
Trimethoprim/Sulphurmethoxazole. If the patient continues to be symptomatic then 
further investigations are carried out (National Department of Health South Africa 
2013:104). 
 
In addition, PHC nurses play an important role in educating the families and 
communities about the importance of seeking medical attention as soon as they 
develop any of the symptoms of TB. The next section discusses the education and 
counselling of MDR TB patients.  
 
2.10 PATIENT EDUCATION, COUNSELLING AND ADHERENCE 
 
One of the dangers for public health is the transmission of MDR TB resulting from 
infectious patients remaining in their community. As discussed earlier, the treatment for 
MDR TB is a lengthy one, and can take as long as 24 months. During this time patients 
require continuous education and counselling in order for them to remain adherent to 
their treatment. However, many people do not take their medication as prescribed and 
this could result in prolonged periods of infectiousness and, more threateningly, the 
emergence of drug resistant strains of the bacteria (Imunya, Kredo & Volmink 2012:2; 
Hirpa, Medhin, Girma, Melese, Mekonen, Suarez & Ameni 2013:1). As the treatment of 
MDR TB is lengthy, involving numerous drugs with adverse effects, treatment disruption 
and non-adherence is a common problem (Podewils, Tarcela, Gler, Quelapio & Chen 
2013:1). Furthermore, other factors that affect adherence to MDR TB treatment include 
loss of a salary as patients are often unemployed, as well as challenges regarding 
availability of second line drugs, substance abuse and psychiatric disorders (Toczek, 
Cox, Du Cros, Cooke & Ford 2012:1). Another reason why patients default in their 
treatment is the absence of symptoms such as fever and cough after the initial phase of 
treatment, leading patients to believe that they are well, as cited in previous studies 
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among drug susceptible TB patients (Munro, Lewin, Smith, Engel & Fretheim 
2007:238). 
 
The WHO endorsed the Directly Observed Treatment Short course (DOTs) Plus 
programme in 2000 (Grover & Takkar 2008:219) which served to complement the TB 
DOTs programme with the exception that MDR TB diagnosis, management and 
treatment are included. According to Hirpa et al (2013:1), DOTs programmes should be 
firmly prescribed, as studies have shown that patients who do not follow a DOTs 
programme are at serious risk of defaulting in treatment and developing MDR TB. The 
DOTs programme also allowed for daily monitoring and the timely management of 
adverse effects, which may promote adherence. Education, counselling and emotional 
support are particularly important for patients diagnosed with MDR TB, much as in any 
other chronic, life-threatening illness. On-going intensive counselling will also help to 
ensure good adherence to the treatment regimen and increase the likelihood of a 
successful outcome (National Department of Health South Africa 2013:93).  
 
The South African National Department of Health MDR TB guidelines (2013) indicate 
that patients and their families should also be informed on an on-going basis about how 
MDR TB is spread and how it can be prevented and treated. In addition the patients 
should be educated about the potential adverse effects of the medication and the need 
to adhere to it should be stressed. Nurses at PHC facilities play an important role as 
they are in contact with the MDR TB patients weekly and can counsel and educate 
patients regarding MDR TB.  
 
2.11 INFECTION CONTROL PLAN 
 
One of the reasons for a high incidence of TB in South Africa comprises the poor 
infection control measures at PHC facilities (Sissolak et al 2011:8; Engelbrecht & Van 
Rensburg 2013:221). Not only is it important to halt the spread of TB and MDR TB 
amongst patients, but it is also important to protect the staff working in PHC facilities 
from infectious diseases. The staff that work at facilities are at higher risk of becoming 
infected with TB and MDR TB, especially if they are immunocompromised due to HIV 
(WHO 2008:ii). The South African guideline on the management of MDR TB indicates 
that the development of the infection control plan is specific for each area and 
occupational group in a facility. A facility may contain a combination of low, 
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intermediate, and high-risk areas or occupational groups at the same time (National 
Department of Health South Africa 2013:120). 
 
However, irrespective of the level of risk, the following principles apply for infection 
control: 
 
• Education on the transmission of TB, the consequences of MDR TB, and the 
importance of complying with the infection control policies must be provided at all 
times in facilities. 
• HIV testing must be promoted as there is an increased risk of patients with HIV 
acquiring TB and MDR TB. 
• Staff who are immunocompromised can be offered other areas to work in. 
• There must be infection control policies which include safe waste disposal, and 
these must be implemented in all facilities. 
• There must be policies on cough hygiene and sputum collection (National 
Department of Health South Africa 2013:120). 
 
The policy on cough hygiene is discussed below.  
 
• Cough hygiene  
 
Patients infected with TB may be found in any service area in a PHC facility, including 
voluntary counselling and testing sites, HIV section, maternal and child health, general 
patient waiting area, and chronic section. As TB is an infectious disease, any delays in 
TB diagnosis and treatment initiation, especially under conditions of crowding and poor 
ventilation, facilitate nosocomial transmission of TB among patients and health care 
workers (Basu, Andrews, Poolman, Ghandi & Shah 2007:1500). 
 
The prevention of MDR TB focuses on both the infectious patient (and infected material) 
and on the health care worker at risk of being infected. Good practice entails that all 
patients be instructed to cover their mouths and noses with a handkerchief, surgical 
mask or a tissue when coughing. After use, these materials should be disposed of in 
small plastic or paper refuse bags, which should be regularly changed and discarded 
into larger refuse bags for incineration. Health care workers should wear particulate 
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respirators such as N95 masks, which are impermeable to droplet nuclei, when nursing 
patients or collecting sputum (National Department of Health South Africa 2013:121). 
Several PHC facilities in South Africa have been shown to have poor infection control 
practices and a lack of training for nurses on infection control was highlighted as one of 
the compounding reasons (Engelbrecht & Van Rensburg 2013:225; Mphahlele, Tudor, 
Van der Walt & Farley 2012:8; Sissolak et al 2011:5). Capacitating nurses as regards 
knowledge of infection control will help to provide a safe area for staff and patients 
(Andrews et al 2007:485). 
 
In the next section, the decentralisation of MDR TB management and care will be 
discussed.  
 
2.12 DECENTRALISATION OF MDR TB MANAGEMENT AND CARE 
 
Conventionally, MDR TB treatment has been provided through small, individualised 
programmes with specialist clinical support, typically in dedicated TB hospitals (Cox & 
Ford 2013:1). However, while such a process might work where the number of patients 
are small, in settings like South Africa and Russia, where there is a large burden of 
MDR TB patients, centralised programmes requiring specialist support are unlikely to 
meet the need (Cox & Ford 2013:1). To that end, many countries have begun to move 
from managing MDR TB in terms of a centralised model to incorporating a decentralised 
model of care.   
 
Decentralised management of MDR TB refers to the transfer of responsibility for treating 
MDR TB patients to lower levels of the system, such as PHC facilities. There are many 
barriers to the access to MDR TB treatment, ranging from insufficient funding, poor 
laboratory diagnostic capacity and health system challenges (Fitzpatrick & Floyd 
2012:63) as well as limited specialist hospitals and bed space to treat patients (National 
Department of Health South Africa 2011:1). One of the factors promoting the 
decentralised approach was that the increased efforts in global TB control had resulted 
in strong basic TB programmes in PHC settings.  It is feasible that integration of MDR 
TB care and management into these routine TB programmes at PHC facilities will allow 
patients with MDR TB to receive treatment close to where they live (Cox & Ford 
2013:1). 
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As early as 2003 and 2004, studies conducted in Lima, Peru, showed successful 
treatment of MDR TB patients in a decentralised setting (Mitnick, Bayona, Palacios, 
Shin, Furin, Alcántara, Sánchez, Sarria, Becerra, Fawzi, Kapiga, Neuberg, Maguire, 
Kim & Farmer 2003:119; Shin et al 2004:1529). Since then, other large-scale MDR TB 
programmes have shown that there is improved care and management of MDR TB 
through decentralisation (Malla, Kanitz & Akhtar 2009:6; Brust, Shah, Scott & 
Chaiyachati, Lygizos, Van der Merwe, Bamber, Radebe, Loveday, Moll, Margot, Lalloo, 
Friedland & Gandhi 2012:998). Furthermore, treatment outcomes have not been 
affected, even with programmes that have task shifted initiation of MDR TB treatment to 
trained nurses (Cox & Ford 2013:1). 
 
• Decentralisation of MDR TB in South Africa 
 
In South Africa, the National Department of Health published a policy framework on the 
decentralisation management for MDR TB in 2011. It included the management of MDR 
TB in decentralised MDR TB units, PHC facilities, or in the community, using mobile 
teams and community caregivers and households (National Department of Health South 
Africa 2011:1). 
 
Prior to the decentralised guideline, the South African National Department of Health 
guidelines stipulated that all MDR TB patients should be hospitalised for at least six 
months. However, a clinical audit of MDR TB services in South Africa revealed that the 
current programme was facing many challenges as discussed previously. This included 
delayed initiation of treatment, inadequate bed capacity and poor infection control in 
hospitals as well as poor adherence to treatment which was often caused by the six 
months of hospitalisation where patients are forced to relinquish work and home 
responsibilities (National Department of Health South Africa 2011:1). 
 
According to Padayatchi et al (2010:95), of the 2 472 and 2 572 cases of MDR TB 
diagnosed in KwaZulu-Natal laboratories in 2005 and 2006 respectively, only 56% in 
2005 and 28% in 2006 were treated in hospital. Those patients not treated in hospital 
were either deceased or remained infectious in the community.  The statistics of the 
number of patients diagnosed and the number treated highlighted the discrepancy 
between the number of beds available to treat patients with MDR TB and the actual 
caseload.  In response to this discrepancy the National Treatment Plan introduced the 
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policy of decentralised management for MDR TB in which decentralised MDR TB units 
will initiate and monitor treatment but only of MDR TB cases. Those patients that did not 
need to be hospitalised were to be managed at PHC facilities by nurses (Padayatchi et 
al 2010:95). 
 
As mentioned before, the outcome of a decentralised procedure would decrease the 
number of days between diagnosis and treatment initiation and increase treatment 
coverage of patients. As a result, there would be a reduction in the transmission of MDR 
TB. In addition, it would enable patients to have treatment closer to their homes, 
increasing the social acceptability of treatment as well as adherence to it (Ndjeka 
2013:10). 
 
• Role of primary health care facilities  
 
Primary health care facilities play a significant role in the decentralised model, as it 
intends that patients receive their treatment for MDR TB from the PHC clinic. According 
to the South African guidelines on the Management of MDR TB, the role of the PHC 
nurse includes providing the treatment, monitoring side effects and adherence. The 
PHC nurse must treat minor side effects such as nausea, vomiting and diarrhoea but 
also needs to identify the more serious side effects and refer the patient to a TB 
hospital. Furthermore, the nurse is involved in the provision of education concerning 
MDR TB to the patient and the family, as well as education on household infection 
control policies. Other functions of the PHC nurse involve identifying and managing 
contacts of MDR TB, collecting monthly sputum and other routine tests (National 
Department of Health South Africa 2011:23). 
 
2.13 KNOWLEDGE OF HEALTH CARE WORKERS ON THE MANAGEMENT OF 
MDR TB 
 
There have been few studies documenting the knowledge of nurses with regard to MDR 
TB. A review of the literature from search engines such as CINAHL, Medline and 
Ebscohost® revealed the following studies (Engelbrecht & Van Rensburg 2013; Kiefer et 
al 2009:783; Savicević 2009:484; Sissolak et al 2011:6; Woith et al 2010:1491). 
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As previously mentioned, a quantitative study in Peru revealed a lack of knowledge 
amongst doctors and nurses regarding assessing treatment outcomes of TB (Kiefer et 
al 2009:783; Savicević 2009:484). In South Africa, a qualitative study conducted in the 
Western Cape investigated the experiences of nurses in South Africa, with regard to the 
factors influencing TB infection prevention and control. The study highlighted a lack of 
TB-related training amongst nurses as one of the challenges facing them (Sissolak et al 
2011:6). Areas identified by Sissolak et al (2011:10) as requiring training included 
infectious time and infection control. The study also emphasised that effective TB 
infection prevention and control practices by nurses were hampered by the lack of clear 
TB policy directives; the lack of appropriate isolation facilities and availability of personal 
protective equipment; the lack of TB training for staff and patients and a persistent work 
overload. Through on-going training and continuing professional development, nurses 
could develop the skills and enhance their confidence in TB and HIV care in a high 
burden environment as well as make informed clinical judgements on appropriate 
management (Sissolak et al 2011: 8). A cross sectional study of 127 PHC facilities in 
South Africa also indicated that there was a gap in the knowledge of nurses regarding 
TB and infection control which could result in an increased risk of nurses contracting TB 
and MDR TB (Engelbrecht & Van Rensburg 2013:225). Another study by Mehtar 
(2008:321) showed that all health care staff, including support staff, must receive 
training in infection control. In a retrospective study conducted in KwaZulu-Natal 
amongst doctors and nurses, a lack of knowledge of the storage of sputum was 
highlighted as a challenge (Loveday et al 2008:1045). 
 
The guideline for decentralised MDR TB management in South Africa states the 
importance of including MDR TB into the nursing curriculum. While the management of 
drug susceptible TB is covered in the nursing curriculum, there is very little coverage of 
MDR TB (National Department of Health South Africa 2011:61). In 2012, DENOSA 
trained nurse educators regarding MDR TB so that in the future, the content could be 
incorporated into their curriculum when training nursing students (DENOSA 2012:1). 
However, since MDR TB patients are currently being managed at PHC facilities it is 
important for the nurses there to be capacitated with knowledge on MDR TB signs and 
symptoms, treatment, side effects, management of contacts, infection control and 
counselling.  
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The management of MDR TB patients is a relatively new role for nurses at PHC 
facilities, arising from the high numbers of patients requiring treatment. As a result, 
there is a gap in the literature with regard to nurses’ knowledge of managing MDR TB in 
the PHC setting. The findings from this study will be important as it will provide a basis 
of the areas in which MDR TB nurses need to be capacitated.  
 
2.14 CONCLUSION 
 
The literature review presented in this chapter included the epidemiology of TB and 
MDR TB, the development of MDR TB, the symptoms and diagnosis of the disease as 
well as the management of MDR TB, the management of MDR TB contacts and 
decentralisation of MDR TB care. In addition, the literature review assisted in the 
development of the questionnaire by enabling the researcher to identify the relevant 
information and to establish content validity.  South Africa faces a significant burden of 
disease from HIV/AIDS and TB and the health care system is predominately nurse 
based. As a result, nurses need to be capacitated in order to assist in managing the 
country’s burden of disease and meet the country’s health care needs.  
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CHAPTER 3 
 
RESEARCH DESIGN AND METHODOLOGY 
 
 
3.1 INTRODUCTION 
 
While Chapter 2 provided a literature review of MDR TB, this chapter describes the 
research design and methodology, including the target population, data collection and 
analysis. The researcher used a quantitative, descriptive, cross-sectional design in 
order to give a detailed description of nurses’ knowledge gaps on the management of 
MDR TB.  
 
3.2 RESEARCH DESIGN 
 
A research design, according to Babbie (2013:124), allows a researcher to clearly state 
what it is they wish to discover and the methods they will pursue. Polit and Beck 
(2012a:741) offer a closely related definition of design by describing research design as 
the overall plan for addressing a research question, including specifications for 
enhancing the study’s integrity. 
 
Brink, Van der Walt and Van Rensburg (2012:112) describe a quantitative research 
design as a suitable design that provides a description of the situation. In this study, a 
quantitative, descriptive and cross sectional design was utilised to describe the 
knowledge gaps of the respondents by using a questionnaire as a measurement 
instrument. In descriptive research, the researcher can obtain complete and accurate 
information about the characteristics of a particular individual, event or group in actual 
situations. In this study, the population group consisted of nurses working at PHC 
facilities and the information that was required was the gaps in their knowledge 
regarding management of MDR TB. 
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3.2.1 Quantitative research 
 
Quantitative research is a formal, objective and systematic process for generating 
information about the world. Polit and Beck (2012a:739) describe such research as the 
investigation of measurable and quantifiable occurrences. In quantitative research, the 
measurement instrument used allows for the generation of numerical data and statistics 
to interpret, organise and present the data. The advantage of this approach is that it 
allows for generalisable findings (Cottrell & McKenzie 2011:7). In this study, the 
knowledge gaps that nurses have regarding the management of MDR TB were 
quantified using a questionnaire as a measurement test. In addition, the researcher 
chose the quantitative approach because it helped to convert data into numeric indices 
and to employ statistical analysis for the measurement of the knowledge gaps of nurses 
as regards the topic. 
 
3.2.2 Descriptive research 
 
Descriptive studies involve observing, describing and documenting aspects of a 
situation as it naturally occurs (Polit & Beck 2012a:226). These studies do not attempt 
to manipulate or control the respondents but may be used to describe what exists, 
identify problems in current practice, justify current practice, make judgments and 
determine what others are doing in similar situations (Burns et al 2012:225). The 
purpose of this study was to describe the knowledge gaps of nurses working in PHC 
facilities on the management of MDR TB. It did not involve any prediction of any 
occurrence or an explanation of the underlying factors of the variables involved; 
therefore a descriptive design was suitable for the study. Furthermore, descriptive 
studies provide valuable baseline information; in this study, a structured questionnaire 
elicited information regarding the knowledge of nurses on the management of MDR TB 
as well as the training that they had received and required.  
 
3.2.3 Cross-sectional research 
 
Cross-sectional studies entail the collection of data on a cross-section of the population, 
which may comprise the whole population or a sample of it (Holland & Rees 2010:119). 
Collection of data occurs at a point in time, but with differing study respondents, as 
opposed to different points in time for the same respondent (Brink, van der Walt & van 
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Rensburg 2007:10). The researcher chose cross-sectional research for this study, 
because data collected from the respondents occurred at one point in time, as opposed 
to a longitudinal research design whereby data collection from subjects occurs over an 
extended period. Therefore, the data obtained from a sample of the nursing population 
was considered as representative of what was going on at a specific point in time.  
 
3.3 RESEARCH METHODOLOGY 
 
The research method is defined as a systematic approach to the research process and 
explains to the reader how the study was carried out. It includes the population used, 
sampling, data collection and data analysis (Polit & Beck 2012a:59). 
 
3.3.1 Research setting  
 
The research setting is the environment in which the research study takes place and 
may be a natural or controlled environment. Natural settings are real-life study 
environments without any changes made for the purpose of the study (Burns et al 
2012:373). This study was conducted in urban PHC facilities in the Nelson Mandela 
Metropolitan (NMM), Eastern Cape Province of South Africa. The NMM is the third 
largest and most densely populated district in the Eastern Cape Province (Health 
Systems Trust 2013:224). The facilities were selected from the 42 PHC facilities that 
render TB services in the NMM. There are usually two nurses in the TB unit at the PHC 
facilities. Over the past eight years the number of patients visiting PHC facilities has 
doubled and during the 2012-2013 year, the total number of patients receiving care at 
the 42 PHC facilities in the NMM amounted to over 3 million (Health Systems Trust 
2013:224).  In 2011-2012, the total nurse to patient ratio in the NMM was 1:44 (Nelson 
Mandela Metropolitan 2012:20). Some of the existing challenges at PHC facilities 
include the limited staff complement and the fact that the number of facilities has not 
increased significantly. Moreover, the increasing burden of disease caused by HIV/AIDs 
and TB has fuelled the increase in patients seeking care. Studies conducted at other 
PHC facilities in South Africa also indicate a shortage of nurses (Daviaud & Chopra 
2008:48; Nyasulu, Muchiri, Mazwi & Ratshefola 2013:235) and that expanding services 
without the needed increase in the available human and functional space resources 
results in an increased workload at PHC levels (Nyasulu et al 2013:235). Furthermore, a 
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study conducted by Nkosi, Horwood, Vermaak & Cosser (2009:412) illustrated that the 
scope of practice of nurses has broadened in recent years.  
 
At the PHC facilities in the NMM, sessional doctors work at some of the facilities for a 
few hours a day once or twice a week. However, these doctors are usually booked for 
patients requiring chronic disease evaluation, not TB or MDR TB services. This 
shortage of doctors was also revealed in a study conducted by Nkosi et al (2009:412) in 
which the doctors usually worked at more than one facility per day, seeing mostly 
chronic disease patients.  The patients that present to the TB unit are varied and a 
considerable number of them are HIV co-infected (District Health Information System 
2013). Therefore, the nurses play a crucial role in the management of MDR TB, as the 
doctors are not always available to assist.  
 
3.3.1.1 Study population  
 
According to Polit and Beck (2012a:59), a population is defined as all the individuals or 
objects with common, defining characteristics, also known as the target population. The 
accessible population is the aggregate of cases that conform to the chosen criteria and 
that are accessible for a study (Polit & Beck 2012a:274). Polit and Beck (2012a:274) 
further describe the target population as ‘the aggregate of cases about which the 
researcher would like to generalize’. In this study, the target population was the 
professional nurses working in the PHC facilities in the urban area of the NMM district of 
the Eastern Province of South Africa. The accessible population was all the available 
nurses working at the PHC facilities who were willing to participate in the study.  
 
3.3.1.2 Sample and sampling 
 
As previously mentioned, Polit and Beck (2012a:290) describe sampling as the process 
of choosing a portion of the population to represent the entire population and the 
advantage of selecting a sample is that it is less costly and more time saving than 
collecting information from a large group of respondents. The selected sample should 
therefore have characteristics similar to that of the population under study to allow 
generalisability of the results to represent the population (Polit & Beck 2012a:288). In 
quantitative studies, the larger the sample size the lesser the sample error (Brink et al 
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2012:143). There are two types of sampling, probability sampling and non-probability 
sampling. In this study non-probability sampling was employed. 
 
• Non-probability sampling 
 
In non-probability sampling, elements are selected by non-random methods. One such 
type of non-probability sampling is convenience sampling which involves utilising the 
most conveniently available people as respondents (Polit & Beck 2012a:288). Cottrell 
and McKenzie (2011:132) indicate that with convenience sampling respondents are 
selected based on their accessibility and proximity to the researcher and is used 
frequently because it saves time and money. As mentioned before, the distances 
between facilities were large and due to the researcher’s lack of resources and small 
budget, in this study, the convenience sampling technique was used to select the sites.  
It was also based on availability and the willingness of respondents to participate.  
 
As mentioned in Chapter 1, before sampling, the researcher obtained a list of all PHC 
facilities in the NMM. The researcher chose the NMM due to convenience as he resided 
and worked in this metropole. As the distances between these facilities are 
considerable, the researcher selected 25 accessible facilities to be included in the 
study. These sites were chosen using the convenience technique, selecting the sites 
nearest and most available to the researcher.  As convenience sampling was used, no 
statistical formula was used to determine the sample size.  
 
• Inclusion criteria 
 
The criteria specifying the population characteristics are called the ‘inclusion criteria’ 
(Polit & Beck 2012a:274). According to Brink et al (2012:131), it is important for the 
researcher to describe and mention inclusion criteria for the population. As noted, the 
respondents included in this study were all registered nurses working in the PHC 
facilities TB unit who were available and willing to complete the questionnaire. Due to 
the shortage of nurses in this setting, there was no restriction on the length of time that 
the respondents had worked in the facilities. The researcher feared that setting a time 
constraint might limit the size of the population. The number of years of work experience 
in the PHC setting was included in the questionnaire to correlate the influence of work 
experience with knowledge on MDR TB. 
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• Exclusion criteria 
 
Exclusion criteria are those characteristics that the population must not possess (Polit & 
Beck 2012a:274).  In this study, the exclusion criterion was those respondents who 
were not willing to participate. 
 
3.3.1.3 Sample size 
 
Burns et al (2012:367) state that there are no firm rules concerning sample size but that 
a sample should have at least thirty respondents. According to Polit and Beck 
(2012a:285), most nursing studies use samples of convenience. As there are typically 
two registered nurses in the TB unit at a PHC facility, due to the limited scope of this 
study, 50 respondents made up the sample. All the nurses working at the TB units at 
the PHC facilities, who were available and willing to participate in the research, were 
included in the sample. Ultimately, 32 respondents completed the questionnaire and 
were included in this study. As mentioned earlier, the shortage of nurses at the facilities 
due to absenteeism and redistribution of nurses to other areas also contributed to the 
small sample size. The respondents that completed the questionnaire represented the 
study population and this could allow for reliable statistical inferences to be made about 
the study population (Cottrell & McKenzie 2011:134). 
 
3.3.2 Data collection 
 
Data collection is the process of selecting respondents and gathering data from these 
respondents (Burns et al 2012:523). In this study, data were collected using a 
respondent administered structured questionnaire that was hand delivered to the 
respondent, at the PHC facility, by the researcher. The researcher waited for the 
respondents to complete the questionnaires. Those respondents that did not have the 
time to complete the questionnaires kept them; these were collected after one week by 
the researcher. If respondents experienced difficulties answering the questionnaires, the 
researcher was available for clarification while waiting for the completed questionnaire 
and when the questionnaires were collected. The questionnaire elicited demographic 
information from the respondents as well as information regarding the respondent’s 
knowledge about the management of MDR TB and the training they had received 
regarding it. Respondent fatigue was avoided, as the time taken to complete the 
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questionnaire was brief, and ranged from 15 to 20 minutes. The researcher handed out 
50 questionnaires; as mentioned, 32 questionnaires were returned. Collection of the 
data occurred over the period August to October 2013. 
 
3.3.2.1 Data collection instrument 
 
According to Polit and Beck (2012a:328), quantitative studies derive data through the 
measurement of variables. Measurement requires allocation of numbers to represent 
attributes present in the respondents (Polit & Beck 2012a:328). Although it takes a great 
deal of time to develop a well-designed questionnaire, the researcher chose to develop 
a structured questionnaire, because relative to interviews, questionnaires are less costly 
and require less time to administer as well as offering the respondent relative 
anonymity. Some of the disadvantages of questionnaires include poor response rates 
and the possibility of respondents misunderstanding the questions. The researcher 
managed these disadvantages by collecting the questionnaires from the PHC facilities 
as opposed to having them posted. This ensured that the researcher was available at 
the time of issuing and collection of the questionnaires and was able to clarify any 
questions not understood by respondents.  The advantages of using a questionnaire for 
this study were that they allowed the researcher to collect the data from the 
respondents at the same time, enhancing cost effectiveness and that the nurses at the 
PHC facilities, who were very busy, had the option of completing the questionnaire in 
their own time.  
 
The design of the questionnaire was based on the literature review.  
 
• Layout of the questionnaire 
 
Questions on the said questionnaire were written in English. The researcher used the 
same structured questions for all the respondents to ensure consistency of the 
responses. As indicated in Table 3.1, the questionnaire was divided into three sections. 
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TABLE 3.1: SECTIONS COVERED IN THE QUESTIONNAIRE 
SECTION ASPECTS COVERED 
Section 1:  Staff 
demographics 
 
Question 1-6 
 
 
 
Questions required demographic information of respondents’ 
gender, qualifications and experience 
Section 2: Training 
 
Questions 1-3 
 
 
Questions 4-10 
 
 
 
 
Question 11 
 
 
Questions required respondents to indicate if they had 
received training regarding MDR TB 
 
General questions covering Continuing Education courses, 
weekly meetings and updates on MDR TB. Questions covered 
aspects of the training respondents would like to receive, 
including frequency and facilitator.  
 
The question required respondents to indicate if the training 
they had received had prepared them for aspects of MDR TB 
control such as providing medication, educating patients, 
monitoring side effects, screening contacts, sputum collection 
and infection control. 
Section 3: Multidrug 
resistant tuberculosis 
 
Questions 1-7 
 
 
 
Question 8-10 
Likert Scale 
 
 
Questions covered knowledge of management of MDR TB, 
covering: causes, susceptibility, prevention and symptoms of 
MDR TB as well as side effects of treatment. 
 
Questions required respondents to rate if they had adequate 
knowledge on ‘GeneXpert’, contact management and infection 
control.  
 
The Likert scale options of choice included ‘strongly agree’, 
‘agree’, ‘disagree’ and ‘strongly disagree’. 
 
• Refinement of the questionnaire 
 
In this study, the researcher designed the structured questionnaire after performing the 
literature review and with the help of his Supervisor and a statistician (Annexure B 
refers); changes were made according to the recommendations. In Section 3, multiple 
choice questions were altered to a Likert type scale question with four responses (1 for 
strongly agree, 2 for agree, 3 for disagree and 4 for strongly disagree). The researcher 
chose to use a four point Likert scale as it allows the respondents the chance to be 
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thoughtful and choose a response as well as eliminating the possible misinterpretation 
of a mid-point.  
 
• Competency indicator 
 
The questionnaire was submitted to two field experts in order to validate the minimum 
mark that would be required by respondents to indicate their knowledge level. The field 
experts both work at a TB hospital and possess medical degrees. This enhanced the 
validity and the reliability of the questionnaire. A competency score of 50% was set. The 
competency indicator was used to enhance the validity and reliability of this study.   
 
3.3.2.2 Pre-test 
 
Polit and Beck (2012a:738) define the pre-test as the trial administration of a newly 
developed instrument to identify problems or assess time requirements.  The purpose of 
the pre-test is not to answer the research question but to identify and prevent problems 
that may be caused by the parent study (Polit & Beck 2008:213). The researcher pre-
tested the questionnaire with four nurses, involved with MDR TB treatment, at two PHC 
facilities prior to data collection. The facilities who participated in the pre-test were not 
included in the final study. Most of the recommended changes were related to minor 
grammatical aspects. The open ended question ‘Do you think the training has prepared 
you for your job?’ was found to be vague and was changed to be more specific and 
closed-ended. The pre-test enabled the researcher to make the necessary changes to 
the questionnaire as well as determine the amount of time required to complete it.  
 
3.3.3 Data analysis 
 
The purpose of data analysis is to obtain meaning from the data generated during the 
study and involves transforming or coding the data into numbers, obtaining a data set 
and then performing statistical analyses (Polit & Beck 2012a:463-473). In this instance 
the questionnaire was pre-coded with codes designated before data was collected. The 
coding system is indicated in the questionnaire (Annexure B refers). The coded data 
was then entered onto an Excel spread sheet to create a data set; the researcher then 
verified the data by checking for wild codes. Polit and Beck (2012a:465) describe wild 
codes as codes that are not possible and not part of the coding system.  This data was 
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then exported for analysis to a statistical package; the SPSS version 20.0 software, and 
analysed by a statistician. Brink et al (2012:178) indicate that statistics is one of the 
most useful tools available in analyzing quantitative data. Descriptive statistics allows 
researchers to summarise and describe quantitative data (Polit & Beck 2012a:226). The 
descriptive statistics such as frequency, percentage, mean and standard deviations 
were primarily used to describe the data with the results being presented in bar graphs, 
tables and pie-diagrams.  
 
Chi square tests were also used were appropriate to identify whether relationships 
existed between variables.  
 
3.4 VALIDITY AND RELIABILITY 
 
In order to ensure that the results obtained from a research study are of a high quality, 
there are some aspects of the measurement procedures and measurement instruments 
that need to be assessed and to show acceptable levels. Validity and reliability are two 
of the most important concepts in the context of measurement (Delport & Roestenburg 
2011:172). 
 
3.4.1 Validity 
 
Validity is the extent of accuracy of an instrument to measure the construct which it is 
supposed to measure, in the context of the concepts being studied (Polit & Beck 
2012a:336). The four aspects of internal validity are outlined below. In this research two 
aspects of internal validity were achieved: content and face validity. These are 
discussed in more detail.  
 
• Content validity was ensured by conducting a literature review prior to the 
design of the questionnaire. The researcher developed the structured 
questionnaire with the aid of his Supervisor to ensure that it measured the 
desired variables. The questionnaire was then submitted to field experts in order 
to assist in determining a score that could be regarded as the minimum score 
respondents should achieve to be regarded as ‘knowledgeable enough’ on the 
subject of MDR TB. This was termed the competency indicator.  Validity was 
tested during the pre-test conducted prior to the actual research data collection 
  
43 
process. This ensured that all questions asked would be correctly understood, 
and that the researcher was satisfied with responses to questions. Therefore, the 
pre-test improved the internal validity of the questionnaire. The results from the 
pre-test were not included in the final data analysed. All captured data was cross-
checked and proof-read by the researcher to ensure accuracy. 
 
• Face validity refers to whether the instrument appears to measure the variable 
that it claims to measure rather than what it actually measures (Delport & 
Roestenburg 2011:174). To measure face validity, experts within the MDR TB 
field were requested to review the questionnaire used in this study. It was 
decided by the same experts that the competency indicator would be 50%, which 
is the same measure that is mostly used to indicate if a test is passed or not as 
mentioned earlier. The pre-test also assisted the researcher to clarify some of the 
questions and determine that the questions were clear and readable.  
 
• Criterion validity involves correlating what an instrument measures with another 
measure accepted as being valid. Criterion validity considers whether scores in a 
measuring instrument are in agreement with a defined standard instrument that 
covers the same theme (Delport & Roestenburg 2011:174). For this study, the 
researcher designed the instrument, after a literature review, as no other 
instrument that addressed the questions could be found. Thus, the instrument 
designed could not be compared with other questionnaires.  
 
• Construct validity refers to whether an instrument successfully measures a 
theoretical construct or the concepts it set out to measure. The challenge as 
regards construct validation is that the theory itself cannot be measured and 
therefore it would be difficult to determine if a construct in fact actually represents 
theory (Delport & Roestenburg 2011:174) in the case of this study. 
 
3.4.2 Reliability 
 
Reliability refers to the consistency of an instrument in terms of which it measures the 
target attribute and can be equated with a measure’s stability, consistency or 
dependability (Polit & Beck 2012a:331). According to Burns et al (2012:391) internal 
consistency testing is used to address the correlation of various items within the 
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instrument and examines the extent to which all the items in the instrument consistently 
measure a concept. Internal consistency exists in degrees and is usually expressed as 
a form of correlation coefficient, with 1.00 indicating perfect reliability and .00 indicating 
no reliability. Values of 1.00 are not obtained in study results because all instruments 
have some measurement error. A reliability coefficient of 0.80 is considered the lowest 
acceptable value for a well-developed measurement instrument while for a newly 
developed instrument, a reliability of 0.70 is considered acceptable, although 
instruments developed in the last five years reflect internal reliability from 0.60 to 0.69 
(Burns et al 2012:391-392; Polit & Beck 2012a:331). The researcher in consultation with 
a statistician used the Cronbach’s alpha co-efficient to test reliability for this study. In 
addition, the researcher ensured that care was taken to ensure accurate phrasing of 
each question in order to avoid ambiguity and pre-tested the questionnaire before the 
final study.  The C alpha values were calculated for the knowledge questions in Section 
3 of the questionnaire. Only two of the values were below 0.7, that is: 0.4 (How can 
MDR TB be prevented) and 0.6 (What is latent/inactive TB). However, these questions 
were not discarded as they did not approach zero and the reason for the low alpha 
score could have been the low number of questions asked (Tavakol & Dennick 
2011:54). 
 
3.5 ETHICAL CONSIDERATIONS 
 
To ensure that the study was conducted ethically, the researcher observed the 
following: 
 
3.5.1 Permission to conduct the study 
 
The researcher obtained permission to conduct the study from the Higher Degrees 
Committee of the Department of Health Studies, University of South Africa (Annexure 
A); the Eastern Cape Department of Health (Annexure C) and the District Manager of 
Nelson Mandela Metropolitan (Annexure D) and the facility supervisors (Annexure E). 
 
3.5.2  Ethical principles for protecting respondents 
 
The three broad principles on which standards of ethical conduct in research are based 
that were respected in the conduct of this study are, as mentioned: beneficence, respect 
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for human dignity and justice (Polit & Beck 2012a:152). Respondents were recruited at 
the facility by the researcher when he hand delivered the questionnaire and were able 
to decide then whether to participate in the study.  
 
3.5.2.1 Beneficence 
 
Researchers are obliged to protect persons from harm, maximise possible benefits and 
minimise possible harm (Polit & Beck 2012a:152).  The respondents were told that there 
was no foreseeable risk or discomfort as a result of participating in the study. The 
respondents were also informed that there was to be no direct, immediate benefit 
except for the awareness that arose from respondents in identifying their own 
knowledge gaps.  The study findings would assist health services managers in the 
district to improve service delivery. The possible risk of respondents feeling that they 
were incompetent when answering the questionnaire was overcome by ensuring that 
the questions on knowledge were formulated using a Likert scale. These scales do not 
force a respondent to answer Yes or No, but allow the respondent to answer in a 
degree of agreement, thus making the question easier to answer. Respondents were 
assured that the data collected would not be reflecting their competencies but rather 
aspects of the management of MDR TB that required training.  
 
3.5.2.2 Respect for human dignity 
 
According to Polit and Beck (2012a:154), humans should be treated as autonomous 
agents capable of controlling their actions. Researchers have an obligation to respect 
each respondent as a person capable of making a decision regarding participation in 
the study. In this study the researcher, who was not known to the respondents, ensured 
that all respondents received full disclosure of information regarding the nature of the 
study, its purpose and benefits to the district as it will inform the district  regarding the 
training required. According to Polit and Beck (2012a:154), respect for human dignity 
also includes freedom from coercion. Coercion involves explicit or implicit threats of 
penalty from failing to participate on the study or excessive rewards from agreeing to 
participate. The respondents were able to exercise their right to refuse to participate in 
the study. The voluntary completion of the questionnaires implied that informed consent 
was obtained from respondents.  
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3.5.2.3 Justice 
 
In this study the information provided by respondents during data collection was not 
divulged to others without permission. To ensure confidentiality and anonymity, no 
name or any form of identity was required on the questionnaire, thus protecting the 
privacy of any respondent. The respondent was assured that the information they 
provided would be used for research only and that the results of the research would be 
presented to national and international audiences to improve nursing practice.  
 
3.6 CONCLUSION 
 
This chapter described the research methodology including the sample population, data 
collection instruments and strategies to ensure the ethical standards, reliability and 
validity of the study.  
 
The findings of the study are discussed in the next chapter.   
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CHAPTER 4 
 
ANALYSIS, PRESENTATION AND DESCRIPTION OF THE RESEARCH 
FINDINGS 
 
 
4.1 INTRODUCTION 
 
The research design and methodology were described in the previous chapter. This 
chapter presents the research findings with the aid of percentages, tables and graphs. 
The aim of this study, as noted, was firstly to explore the knowledge gaps of nurses 
working at PHC facilities, on the management of MDR TB, in the Nelson Mandela 
Metropolitan. Secondly, it was to enhance the knowledge of these nurses working at 
PHC facilities on the management of MDR TB through recommendations based on the 
findings of this study.  
 
The specific objectives of the study were to: 
 
• Determine the knowledge gaps of nurses working in PHC facilities on the 
management of MDR TB. 
• To propose recommendations to improve the knowledge gaps of nurses working 
in PHC facilities with regard to the management of MDR TB. 
 
The symbol ‘N’ refers to the total number of subjects while the symbol ‘n’ refers to the 
number of subjects in a subgroup of the study (Polit & Beck 2012b:loc 24262). In this 
study ‘N’ refers to the 32 respondents who completed the questionnaire. The symbol ‘f’ 
reflects the frequency of the variables. 
 
4.2 DATA MANAGEMENT AND ANALYSIS 
 
A satisfactory response rate of 64% was achieved as 32 of the 50 questionnaires issued 
were received. Burns and Grove (2009) as cited in Moule and Hek (2011:114), indicate 
that response rates above 50% are regarded as satisfactory. Therefore a total of 32 
respondents took part in the study (N=32). The variation in responses to an item in this 
report is denoted as frequencies (f) and in the text that follows, numerical values unless 
otherwise indicated pertain to the frequencies (f).  
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4.2.1 Section 1: Staff demographics 
 
A total of 32 respondents who met the inclusion criteria participated in this study by 
completing the questionnaires (heading of 3.3.1.3 refers). Questions 1-4 covered the 
demographical data about the nurses working in PHC facilities, which included gender, 
rank category and years of experience. 
 
4.2.1.1 Gender 
 
This question determined the gender of the respondents (N=32). The results are 
reflected in Figure 4.1. As illustrated, the analysis showed that 93.8% (n=30) of the 
respondents were female and 6.3% (n=2) were male. This is in keeping with the general 
trend in nursing in which the number of male nurses is approximately one tenth that of 
female nurses (South African Nursing Council 2013).  
 
 
Figure 4.1: Gender of respondents (N=32) 
 
4.2.1.2 Designation of nurses 
 
The study was intended to target the nurses working in PHC facilities who were involved 
in the provision of TB services. The majority of the respondents, 88.6% (n=31), were 
professional nurses. There were 8.6% (n=3) enrolled nurses who completed the 
questionnaire because, at the time, they were working in the TB unit in the absence of 
the professional nurse. However, these three respondents’ data were not included as 
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they did not meet the inclusion criteria stated in Chapter 3, (heading of 3.3.1.2 refers). 
Of the respondents 2.9% (n=1) completed the section as ‘other’ namely: Facility 
manager. This facility manager was a professional nurse.  
 
4.2.1.3 Number of years since qualified 
 
Table 4.1 indicates that 22% (n=7) of the nurses had qualified less than five years’ ago, 
28% (n=9) had qualified 5-10 years previously, 41% (n=13) of nurses had qualified 11-
20 years ago. Only 9% (n=3) had qualified more than 20 years ago.  
 
TABLE 4.1: WORKING EXPERIENCE SINCE QUALIFICATION AS A PROFES-
SIONAL NURSE (N=32) 
 
YEARS EXPERIENCE f % 
<2 years 2 6 
2-4 years 5 16 
5-10 years 9 28 
10-20 years 13 41 
>20 years 3 9 
 
4.2.1.4 Experience working in the TB section of the PHC facilities 
 
The majority of nurses in the study 71.9% (n=23) had worked in the TB section for less 
than three years (Figure 4.2). The respondents that had four to six years’ experience in 
the TB section was 12.5% (n=4) while 15.6% (n=5) had over seven years’ experience. 
The limited experience could be attributed to numerous factors, including the increase in 
TB infection rates observed, as a result of the HIV epidemic and the limited number of 
health care professionals at the facilities. As a result, there is a high turnover of nurses 
who are required to attend to TB services. As mentioned earlier, this shortage of nurses 
at PHC facilities was also reported by Daviaud and Chopra (2008:48) and Nkosi et al 
(2009:412). A study conducted by Nyasulu et al (2013:235) at PHC facilities in South 
Africa, revealed that providing extra services, such as antiretroviral initiation, without 
increasing the staff complement, increased the workload at the facility.  
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Figure 4.2: Number of years’ working experience in the TB unit of  
PHC facilities (N=32) 
 
4.2.2 Section 2:  Training 
 
This section dealt with the training received on MDR TB and elicited responses on 
aspects such as training frequency, facilitator required and areas that required training.  
 
4.2.2.1 Training received 
 
Table 4.2 illustrates the percentage of respondents that received training on HIV/AIDS, 
MDR TB and decentralisation programme of MDR TB. 
 
TABLE 4.2: TRAINING RECEIVED ON HIV/AIDS, MDR TB AND DECENTRALISA-
TION PROGRAMME (N=32) 
 
TRAINING RECEIVED 
YES NO 
f % f % 
HIV/AIDS 29 91 3 9 
MDR TB 12 38 20 63 
Decentralisation of MDR TB 5 16 27 84 
 
As can be seen from Table 4.2, the majority of respondents, 91% (n=29) had received 
training on HIV/AIDs, while less than half of the respondents, 38% (n=12) had been 
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trained on MDR TB. Only 16% (n=5) of respondents had been trained on the 
decentralisation of MDR TB processes. The HIV/AIDS programme was expanded to 
include nurse initiation of HIV positive patients at PHC facilities in 2011 in the NMM, the 
same year in which the decentralisation of MDR TB was started. The results indicate 
that as opposed to MDR TB, much more training occurred regarding HIV/AIDS. 
 
4.2.2.2 Continuing professional development (CPD)  
 
Only 25% (n=8) of the respondents took part in continuing education programmes 
(Figure 4.3). This could be attributed to the non-compulsory nature of the CPD 
programme. 
 
 
Figure 4.3: Participation in continuing professional development  
programmes (N=32) 
 
4.2.2.3 Weekly meetings to discuss MDR TB patients and challenges 
experienced and point of referral for information 
 
Table 4.3 shows that only 22% (n=7) of the respondents had weekly meetings to 
discuss the MDR TB programme while Figure 4.4 illustrates that the majority of 
respondents, 87.5% (n=28) would go to a colleague when they had questions regarding 
MDR TB patient care.  
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TABLE 4.3: WEEKLY MEETINGS TO DISCUSS THE MDR TB PROGRAMME (N=32) 
 
ATTANDANCE f % 
Yes 7 22 
No 25 78 
 
 
 
Figure 4.4: Point of reference for advice (N=32) 
 
4.2.2.4 Training offered on current information and MDR TB guidelines 
 
When asked whether training on MDR TB was offered with regard to current 
information, updates and guidelines, 78% (n=25) of the respondents responded in the 
negative (Table 4.4). Ninety-one percent (n=29) of respondents responded that they 
would like to receive training on MDR TB (Table 4.5). These results show that, 
according to the respondents, they were provided with very little information regarding 
MDR TB. In a study conducted by Wajanga, Peck, Kalluvya, Fitzgerald, Smart and 
Downs (2014:4) regarding barriers to initiation of ARVs and TB therapy it was found that 
lack of awareness and acceptance of new WHO guidelines and lack of trained staff 
could be addressed by continuing education of the staff. The above results indicated 
that the respondents would like to receive training on MDR TB. 
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TABLE 4.4: FREQUENCY DISTRIBUTION: IS ANY TRAINING OFFERED ON 
CURRENT INFORMATION, UPDATES AND GUIDELINES ON MDR-TB? 
(N=32) 
 
TRAINING OFFERED f % 
Yes 7 22 
No 25 78 
 
TABLE 4.5: FREQUENCY DISTRIBUTION: WOULD YOU LIKE TO RECEIVE 
TRAINING ON MDR TB? (N=32) 
 
WILLINGNESS TO TRAIN  f % 
Yes 29 91 
No 3 9 
 
According to Table 4.6, the majority of respondents, 69% (n=22) indicated that they 
would like training to occur once a quarter. 
 
TABLE 4.6: SCHEDULE FOR IN SERVICE TRAINING (N=32) 
 
SCHEDULE FOR TRAINING f % 
Weekly 1 3 
Monthly 6 19 
Quarterly 22 69 
Yearly 3 9 
 
Ninety-one percent (n=29) of the respondents thought that the most qualified person to 
do this training for them was a doctor (Table 4.7).  
 
TABLE 4.7: FREQUENCY DISTRIBUTION: THE MOST QUALIFIED PERSON TO DO 
THE TRAINING (N=32) 
 
TRAINING FACILITATOR f % 
Doctor 29 91 
Pharmacist 2 6 
Other 1 3 
 
The results show that according to the respondents, the doctor is regarded by the 
respondents as the person most qualified to do the training.  
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4.2.3 Perception of knowledge  
 
When asked whether the training they had received had prepared them for managing 
patients with MDR TB in terms of providing injectables and MDR TB medication, 
educating patients on adherence and MDR TB, monitoring side effects of treatment, 
screening contacts, sputum collection and infection control the response varied 
according to the discipline. Table 4.8 illustrates the results obtained. 
 
TABLE 4.8: RESPONDENTS’ RATING OF THEIR KNOWLEDGE TO MANAGE 
PATIENTS WITH MDR TB (N=32) 
 
KNOWLEDGE ADEQUATE NOT ADEQUATE 
f % f % 
1. Providing injectables 16 50 16 50 
2. Providing MDR TB medication 13 41 19 59 
3. Educating patients on MDR TB and 
adherence 21 66 11 34 
4. Monitoring side-effects of treatment 8 25 24 75 
5. Screening contacts 24 75 8 25 
6. Sputum collection 25 78 7 22 
7. Infection control 23 72 9 28 
 
Table 4.8 illustrates that there is a need for training on MDR TB medication and 
monitoring side effects. The respondents’ rating of their knowledge ranged from 25% 
(monitoring of side effects of treatment) to 78% (Sputum collection), rating their 
knowledge as adequate. The majority of respondents (75% and 78%) had received 
adequate training on screening contacts for MDR TB and sputum collection 
respectively. More than half (72% and 66%) of the respondents indicated that they had 
been given adequate training as regards infection control and educating patients on 
MDR TB and adherence respectively.  
 
4.2.3.1 Comparison of years of experience in TB unit with perceived knowledge 
of managing patients 
 
In order to compare the experience of nurses in the TB unit (Figure 4.2 refers) with their 
perceived adequate knowledge (Table 4.8 refers), Chi square tests were performed as 
the data was categorical, which made cross tabulations possible. Respondents were 
categorised into two groups based on their experience: 1 to 3 years and 4 or more 
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years. The results are shown in Table 4.9 below. In the table n1 represents the number 
of respondents with 1-3 years’ experience and n2 represents the number of 
respondents with 4 and more years’ experience. 
 
TABLE 4.9: COMPARISON OF YEARS’ EXPERIENCE IN TB UNIT WITH 
PERCEIVED ADEQUATE KNOWLEDGE 
 
ADEQUATE KNOWLEDGE  
EXPERIENCE IN TB UNIT CHI 
SQUARE P (df=1) 1-3 YEARS  
(n1=23) 
4+ YEARS 
(n2=9) 
Providing injectables 10 43% 6 67% 1.18 .278 
Providing MDR TB 
medication 7 30% 6 67% 2.86 .091 
Educating patients on MDR 
TB and adherence 14 61% 7 78% 0.27 .603 
Monitoring side-effects of 
treatment 6 26% 2 22% 0.05 .831 
Screening contacts 17 74% 7 78% 0.05 .831 
Sputum collection 18 78% 7 78% 0.20 .654 
Infection control 15 65% 8 89% 0.56 .455 
 
For all of the questions, there was no statistical difference between the groups 1-3 years 
and >4 years. Nevertheless, a trend emerges: the more experienced the group the 
more they rate their knowledge as being adequate. Given the differences between the 
experience of the two groups for most of the knowledge items, the reason that there 
were no statistically significant differences is the small sample size that was used in the 
study.  
 
In the next section, the results of the knowledge questions are presented while in 
Section 4.5, the results of the knowledge indicator are depicted. Section 4.6 illustrates 
the cross tabulation between the number of years with experience in the TB unit and 
Section 3 scores. 
 
4.2.4 Section 3:  Multidrug resistant tuberculosis 
 
The aim of this section was to determine if there were any areas of MDR TB that 
required training to be conducted. Respondents answered a total of 10 questions which 
were designed using a Likert scale scoring from 1 to 4 (strongly agree, agree, disagree 
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and strongly disagree). Each question had three to four statements. Each statement 
elicited a response to one of the statements about MDR TB as a disease. For statistical 
inference purposes because the sample size was small, and to make interpretation 
easier, ‘strongly agree’ and ‘agree’ were combined and ‘strongly disagree’ and 
‘disagree’ were combined.  
 
4.2.4.1 Cause of MDR TB 
 
Almost all the respondents were knowledgeable about the cause of MDR TB, with 84% 
(n=27) of the respondents correctly attributing it to organisms resistant to Rifampicin 
and Isoniazid. However, 31% (n=10) of the respondents also incorrectly agreed that 
Streptomycin in addition to Rifampicin and Isoniazid lead to MDR TB.  
 
TABLE 4.10: FREQUENCY DISTRIBUTIONS FOR QUESTION ON ‘CAUSES OF 
MDR TB’ (N=32) 
 
CAUSES OF MDR TB AGREE DISAGREE 
MEAN SD f % f % 
By an organism resistant 
to Rifampicin 19 59 13 41 2.2.5 0.72 
By an organism resistant 
to Isoniazid 15 47 17 53 2.47 0.72 
By an organism resistant 
to Rifampicin and 
Isoniazid 
27 84 5 16 1.97 0.59 
By an organism resistant 
Rifampicin, Isoniazid 
and Streptomycin 
10 31 22 69 2.72 0.73 
 
4.2.4.2 Who can contract MDR TB? 
 
With regards to who can contract MDR TB, 84% (n=27) of the respondents correctly 
agreed that patients who were not adherent to the TB medications could contract MDR 
TB. Only 53% (n=17) believed that people who came from areas of the world where 
drug resistant TB was common could contract MDR TB (Table 4.11).  Thus, training on 
who can contract MDR TB was required to encompass all possible areas.  
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TABLE 4.11: FREQUENCY DISTRIBUTIONS FOR QUESTION ON ‘WHO 
CONTRACTS MDR TB?’ (N=32) 
 
WHO CONTRACTS 
MDR TB 
AGREE DISAGREE 
MEAN SD f % f % 
People who do not take 
their TB medicines 
regularly 
27 84 5 16 2.03 0.54 
People who come from 
areas of the world where 
drug resistant TB is 
common 
17 53 15 47 2.34 0.70 
People who develop TB 
again after having taken 
TB medicine in the past 
17 53 15 47 2.38 0.66 
 
4.2.4.3 Prevention of MDR TB 
 
Fifty-three percent (n=17) of the respondents correctly agreed that MDR TB cannot be 
prevented. Sixty-three percent (n=20) agreed that MDR TB could be prevented if 
patients took all their medicines as prescribed. However, 72% (n=23) of the 
respondents incorrectly agreed that taking Isoniazid Preventative Therapy (IPT) could 
prevent MDR TB in adults. 
 
TABLE 4.12: FREQUENCY DISTRIBUTIONS FOR QUESTION ON ‘PREVENTION 
OF MDR TB’ (N=32) 
 
PREVENTION OF MDR 
TB 
AGREE DISAGREE 
MEAN SD f % f % 
MDR TB cannot be 
prevented 17 53 15 47 2.28 0.77 
Take all their TB 
medicines as prescribed 20 63 12 38 2.31 0.69 
Take Isoniazid 
preventative therapy (IPT) 
in adults 
9 28 23 72 2.97 0.74 
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4.2.4.4 What is latent/inactive TB? 
 
More than half of the respondents, 63% (n=20) correctly agreed that latent /inactive TB 
was TB infection without active disease. Fifty-three percent (n=17) of the respondents 
answered incorrectly by agreeing that latent TB was sputum smear negative TB and 
75% (n=24) answered incorrectly that latent TB is TB characterised by fever, chills and 
night sweats. 
 
4.2.4.5 Symptoms of MDR TB 
 
There was a general agreement with regard to the symptoms of MDR TB: 78% (n=25) 
to 81% (n=26) of respondents answered correctly (Table 4.13). 
 
TABLE 4.13: FREQUENCY DISTRIBUTIONS FOR QUESTION ON ‘SYMPTOMS 
OF MDR TB’ (N=32) 
 
SYMPTONS OF MDR TB AGREE DISAGREE 
MEAN SD f % f % 
Cough 26 81 6 19 1.94 0.67 
Chest pain, dyspnoea 26 81 6 19 1.97 0.65 
Systemic symptoms (e.g. 
fever, chills, night sweats) 25 78 7 22 2.06 0.62 
 
4.2.4.6 Side effects of MDR TB 
 
Table 4.14 demonstrates that the majority of respondents knew the side effect profiles 
of MDR TB drugs that cause peripheral neuropathy (69%, n=22) and hearing loss (50%, 
n=16). A high number of respondents did not know the side effect profile of MDR TB 
drugs that caused depression (81%, n=26) and psychosis (78%, n=25).  
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TABLE 4.14: FREQUENCY DISTRIBUTIONS FOR QUESTION ON ‘SIDE EFFECTS 
OF DRUGS USED TO TREAT MDR TB’ (N=32) 
 
SIDE EFFECTS OF 
DRUGS USED TO TREAT 
MDR TB 
AGREE DISAGREE 
MEAN SD 
f % f % 
Peripheral neuropathy 
Isoniazid, Cycloserine, 
Ethambutol, injectables 
22 69 10 31 2.06 0.76 
Depression 
Cycloserine, Clofazimine 6 19 26 81 2.75 0.57 
Hearing loss (otoxicity) 
Kanamycin, Streptomycin 16 50 16 50 2.34 0.75 
Psychosis 
Cycloserine 7 22 25 78 2.72 0.68 
 
4.2.4.7 Diagnosis of MDR TB 
 
The respondent responses, as to whether the respondents believed they possessed 
adequate knowledge regarding ‘GeneXpert’, may be seen in Table 4.15. Forty-four 
percent (n=14) of the respondents did not believe they had adequate knowledge 
regarding the use of ‘GeneXpert’ in the diagnosis of MDR TB and 66% (n=21) did not 
have adequate knowledge regarding what to do with patients who had tested positive 
for Rifampicin resistance. The majority of respondents (78%, n=25) did not have 
adequate knowledge on how to manage mono and poly resistant TB.  
 
4.2.4.8 Patient information and Infection control 
 
Table 4.15 indicates that respondents believed they had adequate knowledge with 
regards to counselling and educating patients on MDR TB and infection control, with 
only 28% (n=9) of respondents not having adequate knowledge on how to use an N95 
mask. The majority of respondents had knowledge on how to prevent nosocomial 
infections (91%, n=29) and on sputum collection (91%, n=29). A large number of 
respondents (69%, n=22) did not have adequate knowledge on how to manage 
symptomatic contacts of MDR TB while 50% (n=16) did not have adequate knowledge 
on how to manage asymptomatic contacts of MDR TB. 
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TABLE 4.15: FREQUENCY DISTRIBUTIONS FOR QUESTION ON ‘DO YOU HAVE 
ADEQUATE KNOWLEDGE ON THE FOLLOWING?’ (N=32) 
 
ADEQUATE 
KNOWLEDGE 
AGREE DISAGREE 
MEAN SD f % f % 
The use of ‘GeneXpert’ in 
the diagnosis of MDR-TB 18 56 14 44 2.38 0.61 
What to do with patients 
who test ‘GeneXpert’ 
positive for resistance to 
Rifampicin 
11 34 21 66 2.59 0.61 
How to manage mono 
and poly resistant TB 7 22 25 78 2.72 0.58 
Counsel and educate 
patients on MDR-TB 24 75 8 25 2.22 0.49 
How to manage the 
asymptomatic contacts of 
MDR-TB patients 
16 50 16 50 2.44 0.62 
Managing symptomatic 
contacts of MDR-TB 
patients 
10 31 22 69 2.66 0.55 
Measures to prevent 
nosocomial infection 29 91 3 9 2.06 0.50 
How to use an N95 mask 23 72 9 28 2.22 0.55 
Sputum collection 29 91 3 9 2.06 0.50 
 
4.3 SCALE RELIABILITY MEASURE OF RESPONDENTS’ RESPONSES TO 
KNOWLEDGE ON MDR TB 
 
Section 3 consisted of questions developed to ascertain if there were areas of 
knowledge gaps that required training.  
 
Reliability was measured by means of the Cronbach’s alpha coefficient, calculated as 
part of scale reliability testing for the questions asked. 
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TABLE 4.16: CRONBACH’S ALPHA COEFFICIENT (N=32) 
 
QUESTION CRONBACH’S ALPHA 
Causes of MDR TB 0.72 
Who contracts MDR TB 0.78 
Can MDR TB be prevented 0.70 
How can MDR TB be prevented 0.38 
What is latent/inactive TB 0.64 
Symptoms of MDR TB 0.78 
Side effects of drugs used to treat MDR TB 0.72 
Knowledge on ‘GeneXpert’ 0.89 
Knowledge on counselling and patient contacts 0.72 
Knowledge on infection control 0.66 
 
Of note is that the scales were newly developed and that two of the questions had a low 
Cronbach’s alpha coefficient namely, (i) ‘How can MDR TB be prevented’ (0.38) and (ii) 
‘What is latent/inactive TB’ (0.64). As mentioned, a reliability coefficient of 0.70 or higher 
is considered acceptable (Polit & Beck 2012). The questions with low C alphas were not 
discarded as they did not approach zero and could have resulted due to the small 
number of questions (Tavakol & Dennick 2011:54) and that some of the questions may 
not have been understood. 
 
4.4 COMPETENCY INDICATOR 
 
In this study, the researcher, in consultation with field experts, reached the conclusion 
that a figure of 50% is an indicator of adequate competency. The results of the 
competency indicator are illustrated below.  
  
62 
0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 80.0 90.0 100.0
C3_1_1
C3_1_2
C3_1_3
C3_1_4
C3_2_1
C3_2_2
C3_2_3
C3_3_1
C3_3_2
C3_3_3
C3_4_1
C3_4_2
C3_4_3
C3_5_1
C3_5_2
C3_5_3
C3_5_4
C3_6_1
C3_6_2
C3_6_3
C3_7_1
C3_7_2
C3_7_3
C3_7_4
Mean Percentage
Q
ue
st
io
n
 
Figure 4.5: Average percentage attained for questions 3_1_1 to 3_7_3 (N=32) 
 
Figure 4.5 indicates the average percentages attained by respondents for each question 
in the knowledge section, with the exception of questions 8, 9 and 10. These questions 
reflect the respondent’s opinions regarding their competency level on Diagnosis, Patient 
information and Infection control and are therefore not included in Figure 4.5. The 
results for questions 8, 9 and 10 are displayed in Figure 4.6. 
 
Figure 4.5 illustrates the respondents’ achievement regarding each question, as 
measured in relation to the competency indicator. Respondents met the competency 
level of 50% to 19 (75%) of questions in the questionnaire. However, there are areas of 
MDR TB that require training and capacitating, such as monitoring side effects of MDR 
TB treatment. 
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Figure 4.6 portrays the respondents’ achievements regarding Questions 8, 9 and 10 in 
relation to the competency indicator. Respondents met the competency indicator level 
of 50% in six (67%) of the questions. The areas that need strengthening include 
‘GeneXpert’, managing mono and poly resistant TB and managing symptomatic 
contacts of MDR TB.  
 
 
Figure 4.6:  Average percentage attained for questions (N=32) 
 
4.5 RELATIONSHIP BETWEEN NUMBER OF YEARS’ EXPERIENCE WORKING 
IN A TB UNIT IN PHC FACILITIES AND SECTION 3 SCORES 
 
Cross-tabulations with Chi square tests were used to determine whether the nurses’ 
levels of knowledge (Section 3 sub-sections 1 to 7) and perceived levels of skill (Section 
3 sub-sections 8 to 10) are related to their number of years’ working experience in a TB 
unit in PHC facilities. The respondents were divided into two experience groups: 1-3 
years and 4 and more years, and two knowledge/skills groups, namely <50% and 50% 
or better.  The test results are shown in Table 4.17. Note that C3_1-7 is the average 
score for C3_1 to C3_7 scores. In the table, n1 represents the number of respondents 
with 1-3 years’ experience and n2 represents the number of respondents with 4 and 
more years’ experience.  
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TABLE 4.17: FREQUENCY OF SECTION 3 SUB-SECTION 1 TO 7 SCORES OF 
50% OR BETTER FOR ‘EXPERIENCE WORKING IN THE TB UNIT IN 
PHC FACILITIES’ (N=32) 
 
QUESTIONS 
1-3 YEARS 
n1=23 
4+ YEARS 
n2=9 TOTAL CHI SQUARE 
P 
(df=1)  %  % 
C3_1 19 83 8 89 27 84% 0.11 .741 
C3_2 13 57 6 67 19 59% 0.13 .720 
C3_3 10 43 6 67 16 50% 1.18 .278 
C3_4 17 74 6 67 23 72% 0.35 .552 
C3_5 16 70 8 89 24 75% 0.18 .670 
C3_6 17 74 9 100 26 81% 0.28 .598 
C3_7 11 48 7 78 18 56% 1.58 .209 
C3_1-7 18 78 8 89 26 81% 0.01 .924 
 
The results in Table 4.17 show that there are no statistically significant (p<0.05) 
differences between the two groups for the indicated scores. This could be attributed to 
the small sample size. However, a trend is observable; a larger proportion of the 
respondents with more experience in the TB unit in PHC facilities obtained knowledge 
scores of 50% or better compared to their less experienced colleagues. 
 
4.6 CONCLUSION 
 
This chapter presented the data analysis and interpretation using frequency tables, 
graphs, figures and statistics.  The results of the study revealed the knowledge gaps 
with regard to the management of MDR TB that require further in-service training. Some 
of the areas that require training include ‘patients at risk of contracting MDR TB’, ‘side 
effects of MDR TB treatment’, ‘managing mono and poly resistant TB’ as well as 
‘symptomatic contacts of MDR TB’. In the next chapter, a summary of the research 
findings, the limitations, conclusions and recommendations are presented.  
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CHAPTER 5 
 
FINDINGS, CONCLUSIONS, LIMITATIONS AND RECOMMENDATIONS 
 
 
5.1 INTRODUCTION 
 
Effective and efficient decentralisation of MDR TB services to PHC facilities requires an 
understanding by nurses of the management of MDR TB. The main aim of this study 
was described earlier. Recommendations made were based on the findings of this study 
and achieved through the following objectives: 
 
• The first was to determine the knowledge gaps of nurses working in PHC 
facilities on the management of MDR TB. This objective was met through a 
literature review (Chapter 2) to provide a rationale for the study and to design a 
measuring instrument in the form of a questionnaire (Annexure B). The 
questionnaire determined the knowledge gaps of nurses working in PHC facilities 
on the management of MDR TB (Chapters 3 and 4). 
• The second was to propose recommendations to improve knowledge gaps of 
nurses working in PHC facilities on the management of MDR TB (included in 
Chapter 5). 
 
In this chapter, a brief description of the major findings, conclusions and limitations as 
well as the researcher’s recommendations is given.  
 
5.2 RESEARCH DESIGN AND METHOD 
 
A quantitative, descriptive and cross sectional research design was employed in the 
study in which numerical data were collected at a specific point in time to describe the 
characteristics of the study variables. The research was conducted at 25 PHC facilities 
in the NMM district in the Eastern Cape Province. The data was obtained using a self-
designed questionnaire containing structured and open-ended questions. Respondents 
were included based on the inclusion criteria: nurses working in PHC facilities with MDR 
TB patients. The accessible target population consisted of those nurses working in the 
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TB unit of PHC facilities who were available and willing to participate at the time of the 
study.  
 
Sampling was carried out through convenience sampling: all the nurses working in PHC 
facilities in the NMM who were available and willing were included. Fifty (50) 
respondents from the selected PHC facilities were provided with the questionnaires, of 
which 32 (64%) respondents returned the completed questionnaire. The data were 
analysed using the SPSS version 20.0 software computer programme to generate 
descriptive statistics.  
 
5.3 SUMMARY AND INTERPRETATION OF RESEARCH FINDINGS 
 
This section addresses the interpretation of the findings and conclusions. In the 
following sections N=32.  
 
5.3.1 Findings 
 
The findings dealt with the biographic data and themes identified in the questionnaire as 
nurses’ knowledge gaps related to MDR TB. 
 
5.3.2  Biographic data  
 
Fifty percent (n=16) of the respondents had qualified 11 to >20 years before the study 
was undertaken whereas 72% (n=23) had worked in the TB unit in the PHC clinic for 
less than three years. It seems that although the majority of the nurses reported more 
than 11 years of experience after qualifying as professional nurses, they had limited 
experience in working in the TB unit in the PHC clinic. This could be due to the high 
turnover of nurses that result, due to the chronic shortage of nurses in the PHC 
facilities. Refer to Chapter 3 (heading 3.3.1) for more detail about the research setting. 
 
5.3.3  Themes from the questionnaire 
 
• Training received 
 
The findings regarding the training received by the respondent indicate that only 38% 
(n=12) had received training on MDR TB while even fewer respondents, 16% (n=5) had 
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received training on the decentralized programme. In comparison, 91% (n=29) of 
respondents had received training on HIV/AIDs. This might be the situation because 
previously MDR TB was managed only at TB hospitals (Cox & Ford 2013:645), while 
HIV services at PHC facilities have rapidly expanded (Nyasula et al 2013:235). The 
effects of a lack of training will result in nurses not receiving current information on the 
management of MDR TB and the processes involved in the decentralisation of MDR TB 
patients. There should be a greater emphasis on training the nurses at PHC facilities 
about the management of MDR TB and the decentralisation programme. In addition, 
there should be integration of MDR TB training into HIV/AIDS training by the district 
training coordinators and Non-Governmental Organisations (NGOs) supporting 
HIV/AIDS and TB training in the district. This will ensure greater coverage and 
distribution of MDR TB material.  
 
• Continuing education and weekly meetings 
 
The results indicated that only 25% (n=8) of respondents attend continuing education 
courses. In addition, merely 22% (n=7) of respondents had weekly meetings to discuss 
MDT TB patients and challenges. This could be due to the staff shortages experienced 
at the PHC facilities as well as a lack of time and transportation to attend the courses 
and meetings. This result also emerged in a 2010 study on nurses’ perceptions of 
continuing education in which most of the registered nurses perceived continuing 
education as beneficial to their personal and professional growth and saw that it could 
lead towards improving the quality of patient care (Richards & Potgieter 2010:47). 
Attending continuing education courses will allow respondents to keep abreast with new 
developments in the field of MDR TB and increase their knowledge and skills in its 
management. Not allowing time for regular meetings to discuss MDR TB patient 
management, the challenges experienced and the best practices will hamper the 
personal development of the nurse. Limited weekly meetings also reduce the support 
received by nurses, as they are not able to voice their challenges and brainstorm 
solutions with other nurses working in a similar context. Continuous education could 
also include in-service training and nurses may be asked to identify their training needs 
on the management of MDR TB. Continuing education programmes/in-service training 
should be planned during the afternoons on the days when the PHC facilities are not 
busy so that most of the nurses can benefit. Furthermore, the MDR TB meetings could 
be integrated into the HIV/AIDS meetings. In this way the nurses will not have to leave 
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their facilities more than once in order to attend meetings. Nurses can identify a 
‘meeting’ day once a week that will fit the schedules of the stakeholders and the 
facility’s routines. 
 
• Knowledge on causes and risk of contracting MDR TB 
 
The findings revealed that respondents possessed varying degrees of knowledge 
regarding MDR TB. Eighty-four percent (n=27) of respondents were knowledgeable 
regarding the cause of MDR TB and also agreed that patients who were not adherent to 
their TB medication were at risk of contracting MDR TB. However, only 53% (n=17) of 
respondents believed that people who came from areas of the world where drug 
resistance TB was common were at a high risk of contracting MDR TB. Although a large 
percentage of respondents were knowledgeable about the causes and risks of 
contracting MDR TB, it is crucial that nurses’ knowledge on these aspects relating to 
MDR TB be enhanced. They play a key role in providing health education to patients 
and their families and should be very knowledgeable concerning the causes and risks to 
provide relevant and recent information. This may enhance the prevention of MDR TB, 
as adherence to medication may increase. Pamphlets and posters may assist nurses 
during health education to convey relevant and recent information to patients and family 
members. 
 
• Isoniazid Preventative Therapy (IPT) 
 
Seventy-two percent (n=23) of the respondents indicated that IPT could be used to 
prevent MDR TB in adults. According to the NDOH guidelines, IPT can be used to 
prevent TB but not MDR TB. These results therefore indicate that there is a need to 
ensure that the reason why IPT is prescribed is understood. Heading 2.8, Management 
of MDR TB Contacts in Chapter 2, refers. The danger of giving IPT to adult patients to 
prevent MDR TB is that it will not be effective. With MDR TB, there is resistance to 
Isoniazid and Rifampicin; issuing IPT will increase the possibility of the patient 
contracting Isoniazid-induced hepatitis as seen in a study conducted by Smieja, 
Marchetti, Cook and Smaill (2000). The guideline for Tuberculosis Preventative Therapy 
should be explained in the context of MDR TB. It is recommended that pharmacists and 
doctors promote nurses’ knowledge on IPT and the risk of Isoniazid-induced hepatitis 
through in-service training. It can be recommended as a discussion point during the 
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weekly MDR TB meetings mentioned earlier, to create awareness among nurses 
working in PHC settings. 
 
• Side effects of MDR TB drugs 
 
Another important area in which a knowledge gap was identified was that of the side 
effects of the MDR TB drugs. Only 19% (n=6) of the respondents could link the correct 
drug to the side effect of depression and 22% (n=7) linked the correct drug to the side 
effect of psychosis while 50% (n=16) knew which drugs caused hearing loss. Patients 
receive their MDR TB treatment from PHC facilities and should be monitored for the 
side effects of this regime by the nurses. The nurse can manage minor side effects and 
refer the more serious ones to a doctor. Brust et al (2012:6) found that 99% of the MDR 
TB patients monitored experienced at least one side effect during their treatment, most 
of which were mild and did not require a change in treatment, although 8% experienced 
a severe side effect such as hearing loss. Thus, an increase in the knowledge of the 
nurse regarding the side effects of the medications will allow them to refer the patient to 
the doctor for either a change in regimen or monitoring. Hirpa et al (2013:1) stated that 
one of the key factors affecting non-adherence to medication comprises the negative 
side effects. One of the inherent dangers with this infectious disease is that non-
adherence to MDR TB medication is a risk factor for developing Totally Drug Resistant 
Tuberculosis which is almost untreatable (Matteelli, Roggi & Carvalho 2014:112). 
Nurses should be trained about recognising the side effects of MDR TB medication in 
order to improve the outcomes for the patient by decreasing non-adherence. 
 
• Counselling, infection control and managing contacts  
 
Seventy-five percent (n=24) of the respondents, were knowledgeable regarding 
counselling patients on MDR TB, while 91% (n=29) were knowledgeable regarding 
prevention of nosocomial infection and sputum collection. However, 28% (n=9) of the 
respondents did not know how to use an N95 mask. In addition, only 31% (n=10) and 
50% (n=16) of the respondents respectively knew how to manage symptomatic and 
asymptomatic contacts of MDR TB. One of the dangers of not using an N95 mask 
correctly is the nurse contracting TB or MDR TB (Woith et al 2010:1489; Engelbrecht & 
Van Rensburg 2013:221). It is recommended that an infection control specialist with a 
focus on infection control and the correct use of the N95 mask should perform regular 
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in-service training, especially for new staff. It is crucial for nurses to know how to collect 
sputum as they perform sputum collections on a regular basis. Sputum should be 
collected through the correct procedure to ensure the correct diagnosis and 
management of MDR TB. It is recommended that posters demonstrating the correct 
technique be distributed and placed near areas where sputum is collected in PHC 
facilities to enhance the knowledge of sputum collection techniques for health care 
practitioner and nurses. 
 
• Comparison of working experience in TB unit with knowledge 
 
When comparing the number of years’ working experience in the TB unit in PHC 
facilities with the knowledge scores, the results from the Chi square analysis indicate 
that in general the nurses with a greater number of years’ experience in the TB unit, 
namely >4 years, demonstrated higher knowledge scores. However, the differences 
between the two groups were not significantly large and therefore not statistically 
significant. Recruitment of and retaining nurses working in the PHC setting are crucial to 
alleviate the shortage of nurses in this setting. More nurses in this setting will decrease 
the workload and may enhance job satisfaction. This may lead to nurses working longer 
in the PHC setting, increasing their exposure to continuous training, resulting in 
improved knowledge and skills which may improve patient outcomes. It is 
recommended that salaries and benefits for nurses working in the said setting be 
reconsidered as a recruitment strategy. 
 
The results yield a good average score for all the knowledge questions (61%). The area 
that obtained less than 50%, which was the competency indicator level set, was that of 
‘Side effects of MDR TB medication’ with an average score of 40%. The average score 
for ‘diagnosis of MDR TB’ was 59%. As discussed earlier, MDR TB treatment spans 18-
24 months and there is a high risk of side effects occurring. Side effects must be 
detected at the earliest opportunity to prevent non-adherence and default in treatment 
as this could result in Totally Drug Resistant strains of TB, increasing patient mortality. 
Nurses need to be capacitated so that they are able to recognise and monitor the side 
effects of the MDR TB medication and manage or refer patients accordingly. 
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5.4 CONCLUSION 
 
The results from this study indicated that the knowledge of the participating nurses is 
above that of the competency indicator; however, in comparison to training on 
HIV/AIDS, training on MDR TB and the decentralisation process was slow. In addition, 
there was limited involvement in Continuing Education courses and a lack of weekly 
meetings to discuss challenges experienced in MDR TB programme. There are also 
many areas identified that require further training. These include side effects of MDR TB 
medication, managing mono and poly resistant TB, as well as managing symptomatic 
contacts of MDR TB. In keeping with this, and as more MDR TB patients are 
decentralised to PHC facilities, there will be a greater need for nurses to possess 
knowledge of the management of MDR TB patients.  
 
5.5 RECOMMENDATIONS 
 
Recommendations were based on the findings of this study and address nursing 
practice, education and research. The research findings will be made available to the 
district at the end of the study.  
 
5.5.1 Recommendations for nursing practice 
 
Nurses at PHC facilities usually undertake numerous activities such as providing 
injectables and medicines to all MDR TB patients; monitoring side effects of medicines; 
screening, testing and managing symptomatic contacts and high risk groups; sputum 
collection and counselling MDR TB patients; amongst others. 
 
The following recommendations are made to enhance nursing practice: 
 
• The availability of reference guides on the side effects of MDR TB medication 
should be improved at the PHC facilities. It is recommended that pharmacists 
make these reference guides available to the given facilities on a quarterly basis. 
• Improve the sputum collection procedures of health care practitioners, nurses 
specifically, through distributing the National policy guidelines for sputum 
collection at the PHC facilities. This may be achieved through posters being 
placed in the facilities. 
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• Integration of the screening of all MDR TB contacts into other PHC areas such as 
chronic care, acute care, immunisation, mother and child consultations. Nurses 
can create awareness through health education and perform screenings during 
routine consultations to improve early MDR TB identification. 
• Distribution of the national MDR TB guidelines to all PHC facilities and increasing 
their applicability by provision of posters or pamphlets for nurses to enhance their 
knowledge and address knowledge gaps. 
• Training of nurses at PHC facilities by medical practitioners or TB specialists to 
improve their knowledge on the management of these patients, contacts and 
referral pathways. 
• Training of nurses at PHC facilities by the district TB coordinators on the process 
of decentralisation of MDR TB in the district in order to equip the PHC nurses 
with the operational procedures involved. 
• Nurses trained will be followed up by the district TB coordinators to ensure that 
the information received is implemented. 
 
5.5.2 Recommendations for nursing education/training 
 
The knowledge gaps found in this study relate to education and training. The following 
recommendations are made to enhance these two areas: 
 
• MDR TB and the management thereof should be included in the content of 
nursing curriculums for diploma and degree courses. 
• Regular in-service training programmes on the management of MDR TB should 
be conducted once every quarter for nurses in the PHC facilities to ensure that 
nurses are kept abreast of the latest recommendations as well as to address the 
identified knowledge gaps. The key areas that need prioritising include MDR TB 
medication and side effects, managing symptomatic and asymptomatic contacts 
and infection control methods such as use of an N95 mask. These training 
programmes can be developed and presented by TB experts in the district; TB 
programmes in the Department of Health might be facilitated twice a year to 
improve knowledge and skills of MDR TB of nurses working in the PHC setting. 
• Training to improve nurses’ knowledge on MDR TB guidelines could be 
conducted every three months utilising the National Department of Health’s 
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guideline on Management of Drug resistant tuberculosis and the National 
Department of Health’s Decentralisation of MDR TB policy guidelines and 
Infection Control. The training could be conducted by the Department of Health 
training centre as well as by the NGOs giving support to the district. 
• Training nurses regularly, once every quarter on ‘GeneXpert’ diagnosis by 
medical practitioners or TB experts. 
 
5.5.3 Recommendations for further research 
 
• Efforts should go towards further research to improve the management of 
patients with MDR TB by health care workers such as doctors, nurses and 
pharmacists, either by using the same study or designing a similar study but 
involving other multi-disciplinary team members. 
• Further research should also be conducted with patients as the study group to 
evaluate the patients understanding of MDR TB, the causes, prevention and 
treatment. 
 
5.5.4 Tools developed by the researcher to enhance the knowledge of nurses on 
MDR TB 
 
The researcher, in response to the request received by the respondents at the time of 
issuing and receiving the questionnaires, developed the following tools to assist the 
nurses in their activities. 
 
• one page quick reference to the drug doses for MDR TB medication for adults 
(refer to Annexure F) 
• one page guidance on how to wear an N95 mask (Annexure G) 
• patient’s diary cards for patients to remember their next facility appointment dates 
(Annexure H) 
• pocket guide on the management of MDR TB including drug side effects 
(Annexure I) 
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5.5.5 Additional tools and programmes to be developed 
 
The researcher plans to develop the following programmes in future: 
 
• algorithms summarising the guidelines for easy and quick reference by nurses 
• working with NGO partners and the district to develop a system involving cell 
phone reminders for patients’ appointment dates so as to combat non adherence 
• budgeting for and procurement of pill boxes especially for elderly patients, and or 
co-infected patients who have a large number of medications to take and hence 
are often non-compliant with their medication 
• working with the district pharmacist to enrol all eligible nurses at PHC facilities on 
the dispensing course 
• designing a drug supply management tool for nurses in PHC facilities – a one 
page document to assist with the formulas required to quantify and forecast the 
amount of drugs to be ordered 
• mentoring nurses at PHC facilities on the storage of drugs 
• including community care workers in training programmes so that they 
understand the causes and prevention of MDR TB, infection control mechanisms 
and patient counselling. 
 
5.6 SIGNIFICANCE OF THE STUDY 
 
This study’s findings may create awareness concerning the knowledge gaps of nurses 
working in PHC facilities as regards the management of MDR TB. The findings 
identified the existing knowledge gaps and made recommendations for nursing practice, 
education and research. These may contribute to the health priorities of the district as 
well as partner organisations, who implement TB and HIV collaborative activities, as an 
input during intervention plans and operational research. This may result in the scaling-
up of decentralisation programmes in the NMM and the Eastern Cape. In addition, 
findings of this study may contribute as a reference guide to individual researchers who 
are assessing the MDR TB knowledge of nurses working in PHC facilities. 
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5.7 LIMITATIONS OF THE RESEARCH 
 
The study focused on PHC facilities in the NMM in the Eastern Cape; therefore the 
findings cannot be generalised to other areas. However, it is likely that similar issues 
are prevalent in other South African provinces. As the control of TB and MDR TB is a 
national health priority, similar studies should be considered in these settings. 
Furthermore, although the data were collected using a structured questionnaire another 
limitation is that the information was self-reported; one cannot discount the existence of 
a personal desirability bias, meaning that respondents might not have reported their 
actual knowledge. A further limitation was the small sample size. Although 50 
respondents were invited to participate in the study, only 32 submitted the completed 
questionnaire. One of the reasons for this small number could be the shortage of nurses 
at PHC facilities and the extra workload experienced by these nurses hindering them 
from completing the questionnaire. Chapter 3, section 3.3.1, Research setting, refers. 
 
5.8 CONCLUDING REMARKS 
 
The present study determined the knowledge of nurses working in PHC facilities on the 
management of MDR TB in the NMM. The findings and recommendations could serve 
to further improve the knowledge of nurses and health care providers regarding the 
management of MDR TB, resulting in improving the management of patients diagnosed 
with this disease. This will eventually increase the wide implementation of MDR TB 
management at PHC facilities, not only in the NMM but also in the entire country. The 
researcher also believes this study will contribute significantly to further research into 
effectively ensuring the success of the decentralisation of the MDR TB programme in 
the country.  
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ANNEXURE A 
 
  
1 
 
ANNEXURE B 
HEALTH CARE WORKER QUESTIONNAIRE 
___________________________________________________________________ 
INSTRUCTIONS 
This questionnaire is directed to the nurses working in the TB unit.  
 
Please answer all questions. 
 
Please tick with an (X) in the relevant blocks. Give comments where necessary. 
 
Thank you for your valuable contribution and for taking the time to complete this 
questionnaire. The results obtained from this study will enable the researcher to make 
recommendations on the gaps identified.  
 
Please feel free to contact Vikesh Singh, if you have any difficulties or queries, on 
0741622907. 
___________________________________________________________________ 
CLINIC:  …………………………… 
DATE:  ……………………………... 
 
SECTION 1: STAFF DEMOGRAPHICS 
1. What is your gender? 
1 2 
male female 
 
2. What is your age group? 
1 2 3 4 5 
25-30yr 31-35yr 36-40yr 41-45yr 46-55yr 
 
 
3. Please state your qualifications. 
1 2 
Diploma Degree 
 
  
2 
 
4. What is your designation? 
1 2 3 4 
Auxiliary nurse Enrolled nurse Professional nurse Other 
 
 If other, please specify: 
 _________________________________________________________ 
 
5. How many years since you qualified? 
1 2 3 4 5 
<2 years 2-4 years 5-10 years 10-20 years >20 years 
 
 If other, please specify: 
 _________________________________________________________ 
 
6. How many years’ experience have you had in the TB unit? 
 1 2 3 4 
1-3 years 4-6 years 7-9 years >10 years 
 
 
SECTION 2: TRAINING 
1. Have you received training on HIV/AIDS? 
1 2 
Yes No 
 
2. Have you received training on MDR-TB? 
1 2 
Yes No 
 
3. Have you received training on the decentralisation of MDR-TB? 
1 2 
Yes No 
 
  
3 
 
4. Do you attend Continuing Education Courses? 
1 2 
Yes No 
 
5. Do you have weekly meetings to discuss MDR-TB patients and challenges 
experienced in the management of MDR-TB patients? 
1 2 
Yes No 
 
6. If you have questions regarding MDR-TB patients’ care where do you go to for 
answers? 
1 2 3 
Friend Colleague  specify 
 
 If other, please explain: 
 _____________________________________________________________ 
 
7. Is any training offered on current information, updates and guidelines on MDR-
TB? 
1 2 
Yes No 
 
8. Would you like to receive more training on MDR-TB? 
1 2 
Yes No 
 
9. How often would you like training to occur at the facility? 
1 2 3 4 
Weekly Monthly Quarterly Yearly 
 
10. Who do you think would be the most qualified person to do the training? 
1 2 3 4 
Doctor Nurse Pharmacist Other, 
please 
specify 
 
  
4 
 
11. Do you think the training you have received has prepared you for managing 
patients with MDR-TB in terms of providing injectables and MDR-TB medication, 
educating patients on adherence and MDR-TB, monitoring side effects of 
treatment, screening contacts, sputum collection and infection control? 
  
 Adequate Not adequate 
1. Providing injectables   
2. Providing MDR-TB 
medication 
  
3. Educating patients on 
MDR-TB and 
adherence 
  
4. Monitoring side-
effects of treatment 
  
5. Screening contacts   
6. Sputum collection   
7. Infection control   
 
 
SECTION 3: MULTIDRUG RESISTANT TUBERCULOSIS 
Please mark the most appropriate number for each statement.  
1= strongly agree 2=agree 3=disagree 4=strongly disagree 
 
CAUSES OF MDR-TB AND SYMPTOMS 
Question 1: What causes MDR TB? 
 1= strongly 
agree 
2=agree 3=disagree 4=strongly 
disagree 
MDR TB is caused by an organism 
resistant to Rifampicin 
    
MDR TB is caused by an organism 
resistant to Isoniazid 
    
MDR TB is caused by an organism 
resistant to Rifampicin and Isoniazid 
    
MDR TB is caused by an organism 
resistant Rifampicin, Isoniazid and 
Streptomycin 
       
 
  
5 
 
Question 2:  Who contracts multidrug resistant tuberculosis? 
 1= strongly 
agree 
2=agree 3=disagree 4=strongly 
disagree 
People who do not take their TB 
medicines regularly 
    
People who come from areas of the 
world where drug resistance TB is 
common 
    
People who develop TB again after 
having taken TB medicine in the past 
    
 
Question 3: Who is at risk of getting MDR TB? 
 1= strongly 
agree 
2=agree 3=disagree 4=strongly 
disagree 
People who do not take their TB 
medicines regularly 
    
People who come from areas of the 
world where drug resistance TB is 
common 
    
People who develop TB again after 
having taken TB medicine in the past 
    
 
Question 4: How can MDR TB be prevented? 
 
 1= strongly 
agree 
2=agree 3=disagree 4=strongly 
disagree 
MDR TB can’t be prevented 
 
    
Take all their medicines as 
prescribed 
    
Take isoniazid preventative therapy 
for adults (IPT) 
    
 
Question 5: What is latent/inactive TB? 
 
 1= strongly 
agree 
2=agree 3=disagree 4=strongly 
disagree 
Sputum smear negative TB 
 
    
TB characterised by fever, chills and 
night sweats but no cough 
    
TB that requires treatment with first-
line therapy 
    
TB infection without active disease     
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Question 6: The symptoms of drug resistant TB are? 
 1= strongly 
agree 
2=agree 3=disagree 4=strongly 
disagree 
Cough 
 
    
Chest pain, dyspnoea 
 
    
Systemic symptoms (e.g. fever, 
chills, night sweats) 
    
 
PRICIPLES OF THERAPY AND SIDE EFFECTS of DRUGS USED TO TREAT MDR TB? 
Question 7: The side effects of drugs used to treat MDR-TB are caused by the following 
medication: 
 1= strongly 
agree 
2=agree 3=disagree 4=strongly 
disagree 
Peripheral neuropathy –  
Isoniazid, Cycloserine, Ethambutol, 
injectables 
    
Depression – 
Cycloserine, Clofazimine 
    
Hearing loss (otoxicity) – 
Kanamycin, Streptomycin 
    
Psychosis –  
Cycloserine 
    
 
DIAGNOSIS 
Question 8: I have adequate knowledge on the following: 
 1= strongly 
agree 
2=agree 3=disagree 4=strongly 
disagree 
The use of GeneXpert in the 
diagnosis of MDR-TB 
    
What to do with patients who test 
GeneXpert positive for resistance to 
Rifampicin 
    
How to manage mono and poly 
resistant TB 
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PATIENT INFORMATION 
Question 9: I have adequate knowledge on the following: 
 
 1= strongly 
agree 
2=agree 3=disagree 4=strongly 
disagree 
Counsel and educate patients on 
MDR-TB 
    
How to manage the asymptomatic 
contacts of MDR-TB patients 
    
Managing symptomatic contacts of 
MDR-TB patients 
    
 
INFECTION CONTROL 
 
Question 10: I have adequate knowledge on the following: 
 
 1= strongly 
agree 
2=agree 3=disagree 4=strongly 
disagree 
Measures to prevent nosocomial 
infection 
    
How to use an N95 mask     
Sputum collection     
  
ANNEXURE C 
 
  
ANNEXURE D 
 
  
ANNEXURE E 
 
 
  
ANNEXURE F 
DOSING OF STANDARD MDR TB REGIMEN IN ADULTS 
 
MDR TB Standardised Treatment Regimen for Adults and Children >8 Years – 
Intensive phase: Treatment taken at least 6 times weekly for at least 6 months, guided 
by TB culture conversion 
 
Drug 
 
Dose (<33kg) Dose (33-
50kg) 
Dose (51-
70kg) 
Dose (>70kg) 
Kanamycin 
 
15-20mg/kg 500-750mg 1000mg 1000mg 
Moxifloxacin 
 
400mg 400mg 400mg 400mg 
Ethionamide 
 
15-20mg/kg 500mg 750mg 750-1000mg 
Pyrazinamide 
 
30-40mg/kg 1000-1750mg 1750-2000mg 2000-2500mg 
Terizidone 
 
15-20mg/kg 750mg 750mg 750-1000mg 
 
 
 
 
MDR TB Standardised Treatment Regimen for Adults and Children >8 Years – 
Continuation phase: Treatment taken at least 6 times weekly for at least 18 months 
following culture conversion 
 
Drug 
 
Dose (<33kg) Dose (33-
50kg) 
Dose (51-
70kg) 
Dose (>70kg) 
Ethionamide 
 
15-20mg/kg 500mg 750mg 750-1000mg 
Pyrazinamide 
 
30-40mg/kg 1000-1750mg 1750-2000mg 2000-2500mg 
Moxifloxacin 
 
400mg 400mg 400mg 400mg 
Terizidone 
 
15-20mg/kg 750mg 750mg 750-1000mg 
 
 
 
  
ANNEXURE G 
HOW TO WEAR AN N95 MASK 
 
Prior to wearing the N95 mask, inspect the mask for damage and contamination. Verify all components 
of the respirator are in good condition (e.g. straps, nose-piece, etc.) 
 
To remove the respirator, hold the respirator with one gloved hand. With the other hand, pull the 
bottom strap over your head, and then pull the top strap off.  Dispose as a bio-hazardous waste. 
 
  
ANNEXURE H 
 S – sputum, H   
 
 
 
D – doctor, N – nurse, C – counsellor, B – bloods, M – medication  D – doctor, N – nurse, C – counsellor, B – bloods, M – medication 
S – sputum, H – hospital     S – sputum, H – hospital 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
D – doctor, N – nurse, C – counsellor, B – bloods, M – medication  D – doctor, N – nurse, C – counsellor, B – bloods, M – medication 
S – sputum, H – hospital     S – sputum, H – hospital 
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ANNEXURE I 
CLINICAL FOLLOW UP DURING M(X)DR 
TREATMENT  Clinical Follow up   Recommended Frequency Evaluation by clinician (if outpatient)  At baseline and at least monthly until culture conversion, then at least every 2-3 months Weight  At baseline, weekly during intensive phase, then monthly BMI  Baseline, then monthly Height  Baseline Side Effect Monitoring  On-going Sign and symptoms of hypothyroidism Monthly Audiometry  Baseline, monthly during injectable, 3 months after injectable stopped Eye test  Baseline, when indicated  Source: South Africa National Guidelines, Management of MDR TB Policy   
              
Pocket guide – Multidrug Resistant TB 
 
 
A GUIDE TO ASSIST NURSES 
 
 
  
DRUG RESISTANT TB – DEFINITIONS  Mono-Resistance: 
• Resistance to ONE first line drug (rifampicin, isoniazid, pyrazinamide or ethambutol)  Poly Resistance: 
• Resistance to TWO or more first-line drugs, but NOT BOTH isoniazid and rifampicin  Multi-Drug Resistance (MDR): 
• Resistance to BOTH isoniazid and rifampicin Extensively-Drug Resistance (XDR): Resistance to isoniazid and rifampicin PLUS a fluroquinolone (ciprofloxacin, levofloxacin, moxifloxacin) PLUS one or more second line injectable drug (kanamycin, amikacin or capreomycin) Source: South African National Guidelines, Management of Drug-Resistant Tuberculosis Policy Guidelines, 2011 Smear Conversion: 
• Two consecutive negative smears, at least 30 days apart Smear Conversion date: 
• Smear conversion date is the date the first negative smear was collected Culture Conversion 
• Two consecutive negative cultures, at least 30 days apart Culture Conversion date: 
           
  STANDARD MDR TB AND XDR TB REGIMENS 
 
MDR TB Intensive phase: Km(Am)-Mfx-Eto-Trd-Z Kanamycin(amikacin)-moxifloxacin-ethionamide-terizidone-pyrazinamide Continue for 4 months after culture conversion, minimum duration 6 months  Continuation phase: Mfx-Eto-Trd-Z Moxifloxacin-ethionamide-terizidone-pyrazinamide Continuation phase ends 18 months after culture conversion 
 
 
XDR TB Intensive phase: Cm-Mfx-Eto-Trd-PZA-PAS-clofazimine Capreomycin-moxifloxacin-ethionamide-terizidone-pyrazinamide-PAS-clofazimine Continue for 4 months after culture conversion, but must be a minimum of 6 months  Continuation phase:Mfx-Eto-Trd-PZA-PAS-clofazimine Continuation phase ends 18 months after culture conversion 
 
 
  
DOSING OF STANDARD MDR TB REGIMEN IN 
ADULTS  Intensive Phase 
MDR TB Standardised Treatment Regimen for Adults 
and Children >8 Years – Intensive phase: Treatment 
taken at least 6 times weekly for at least 6 months, 
guided by TB culture conversion 
 
Drug 
 
Dose 
(<33kg) 
Dose 
(33-
50kg) 
Dose 
(51-
70kg) 
Dose 
(>70kg) 
Kanamycin 
 
 
15-
20mg/kg 
500-
750mg 
1000mg 1000mg 
Moxifloxacin 
 
 
400mg 400mg 400mg 400mg 
Ethionamide 
 
 
15-
20mg/kg 
500mg 750mg 750-
1000mg 
Pyrazinamide 
 
 
30-
40mg/kg 
1000-
1750mg 
1750-
2000mg 
2000-
2500mg 
Terizidone 
 
 
15-
20mg/kg 
750mg 750mg 750-
1000mg  Source:  Management of drug resistant Tuberculosis: Policy guidelines. Updated Jan 2013  
  DOSING OF STANDARD MDR TB REGIMEN IN ADULTS  Continuation phase 
MDR TB Standardised Treatment Regimen for Adults 
and Children >8 Years – Continuation phase: Treatment 
taken at least 6 times weekly for at least 18 months 
following culture conversion 
 
Drug 
 
Dose 
(<33kg) 
Dose 
(33-
50kg) 
Dose 
(51-
70kg) 
Dose 
(>70kg) 
Ethionamide 
 
 
15-
20mg/kg 
500mg 750mg 750-
1000mg 
Pyrazinamide 
 
 
30-
40mg/kg 
1000-
1750mg 
1750-
2000mg 
2000-
2500mg 
Moxifloxacin 
 
 
400mg 400mg 400mg 400mg 
Terizidone 
 
 
15-
20mg/kg 
750mg 750mg 750-
1000mg    Source:  Management of drug resistant Tuberculosis: Policy guidelines. Updated Jan 2013  
  
COMMON SIDE EFFECTS EXPERIENCED DURING MDR 
TB TREATMENT 
DRUG 
 
COMPLAINT/SIDE EFFECT 
Aminoglycosides Hearing loss, Vestibular toxicity, 
Hypokalemia, Hypomagnesemia, Rash 
Amikacin Ototoxicity*, dizziness and hearing loss, 
Renal failure* 
Capreomycin Hearing loss, Vestibular toxicity, 
Hypokalemia, Hypomagnesemia, Rash 
Fluroquinolone Seizures, Headache, GI complaints. 
Rash 
Clofazimine 
 
GI complaints, Rash 
Cycloserine GI complaints, Behavioural changes 
including depression and anxiety*, Rash, 
Peripheral neuropathy, Seizures*, 
Headache*, Psychosis 
Ethambutol 
 
Visual changes, Rash, Headache 
Ethionamide GI complaints (nausea, anorexia)*, 
Hypothyroidism*, Hepatotoxicity*, 
Behavioural changes, Rash, Peripheral 
neuropathy*, Headache 
Isoniazid Hepatotoxicity, Behavioural changes, 
Visual changes, Rash, Bone marrow 
suppression, Peripheral neuropathy, 
Seizures, Headache 
linezolid Visual changes, Rash, Bone marrow 
suppression, Peripheral neuropathy 
Para-Aminosalicylic 
acid 
GI complaints, Hyperthyroidism, 
Hepatotoxicity, Rash 
Pyrazinamide 
 
Hepatotoxicity, Rash Source:  Management of drug resistant Tuberculosis: Policy guidelines. Updated Jan 2013 
  MONITORING DURING M(X)DR TB TREATMENT 
 
MONITORING RECOMMENDED 
FREQUENCY 
Sputum smear At baseline, monthly 
TB culture Baseline, monthly until 
conversion then at least every 
other month 
Drug Susceptibility Testing On admission and if no 
improvement (patient TB culture 
positive on treatment) within 3-6  
months 
Liver Function tests Every 1-3 months if on 
Pyrazinamide or at 
risk/symptoms of hepatitis 
(children: if symptomatic, every 
6 months if on ART) 
Serum creatinine Baseline, monthly while on 
injectable 
Serum potassium Monthly while receiving 
injectable 
TSH Baseline, every 6 months if 
receiving ethionamide and/or 
PAS, monthly monitoring for 
signs of hypothyroidism 
(children: every 2 months) 
HIV and Pregnancy tests Baseline and repeat as 
indicated 
Chest X-ray Baseline, every 6 months, at 
treatment completion, when 
requested by clinician (children: 
every 2-3 months during 
intensive phase) 
Lung CT scan When indicated Source:  Management of drug resistant Tuberculosis: Policy guidelines. Updated Jan 2013 
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